Recombinant Proteins

• 

  Subject Areas on Research

  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. 
  • 14-3-3 proteins are part of an abscisic acid-VIVIPAROUS1 (VP1) response complex in the Em promoter and interact with VP1 and EmBP1. 
  • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. 
  • 2B4 utilizes ITAM-containing receptor complexes to initiate intracellular signaling and cytolysis. 
  • 440-kD ankyrinB: structure of the major developmentally regulated domain and selective localization in unmyelinated axons. 
  • 6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase. 
  • 60-kDa Ro protein autoepitopes identified using recombinant polypeptides. 
  • A 3.8 Å resolution cryo-EM structure of a small protein bound to an imaging scaffold. 
  • A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. 
  • A BMP pathway regulates cell fate allocation along the sea urchin animal-vegetal embryonic axis. 
  • A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial. 
  • A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. 
  • A Step Toward Balance: Thrombin Generation Improvement via Procoagulant Factor and Antithrombin Supplementation. 
  • A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. 
  • A VEGF trap inhibits the beneficial effect of bFGF on vasoreactivity in corporal tissues of hypercholesterolemic rabbits. 
  • A beta-lactam inhibitor of cytosolic phospholipase A2 which acts in a competitive, reversible manner at the lipid/water interface. 
  • A binding site for Pax proteins regulates expression of the gene for the neural cell adhesion molecule in the embryonic spinal cord. 
  • A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. 
  • A cell culture system that enhances mononuclear cell IgE synthesis induced by recombinant human interleukin-4. 
  • A central role for beta-arrestins and clathrin-coated vesicle-mediated endocytosis in beta2-adrenergic receptor resensitization. Differential regulation of receptor resensitization in two distinct cell types. 
  • A chemical method for labeling lysine methyltransferase substrates. 
  • A chimeric kinesin-1 head/kinesin-5 tail motor switches between diffusive and processive motility. 
  • A combination of independent transcriptional regulators shapes bacterial virulence gene expression during infection. 
  • A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. 
  • A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. 
  • A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated. 
  • A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. 
  • A cost analysis of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion. 
  • A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. 
  • A feedback loop in the polo-like kinase activation pathway. 
  • A highly sensitive and specific enzyme-linked immunosorbent assay of antibodies to hepatitis C virus. 
  • A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma. 
  • A member of a family of sulfate-activating enzymes causes murine brachymorphism. 
  • A modified procedure for fast purification of T7 RNA polymerase. 
  • A modified recombinant factor VIIa: can we make it work harder, better, faster, stronger? 
  • A molecular basis for inositol polyphosphate synthesis in Drosophila melanogaster. 
  • A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. 
  • A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. 
  • A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. 
  • A need for effective adjuvants. 
  • A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. 
  • A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. 
  • A novel role for erythropoietin during fibrin-induced wound-healing response. 
  • A novel thermostable branching enzyme from an extremely thermophilic bacterial species, Rhodothermus obamensis. 
  • A nuclear factor-kappaB inhibitor BAY11-7082 inhibits interactions between human endothelial cells, T cells, and monocytes. 
  • A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. 
  • A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. 
  • A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. 
  • A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. 
  • A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. 
  • A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. 
  • A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study. 
  • A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. 
  • A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. 
  • A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. 
  • A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. 
  • A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. 
  • A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. 
  • A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. 
  • A potentially abundant junctional RNA motif stabilized by m6A and Mg2. 
  • A predictive model for neutropenia associated with cancer chemotherapy. 
  • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. 
  • A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. 
  • A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. 
  • A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. 
  • A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. 
  • A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. 
  • A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. 
  • A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. 
  • A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. 
  • A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. 
  • A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. 
  • A role for AQP5 in activation of TRPV4 by hypotonicity: concerted involvement of AQP5 and TRPV4 in regulation of cell volume recovery. 
  • A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. 
  • A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. 
  • A sodium channel mutation identified in Aedes aegypti selectively reduces cockroach sodium channel sensitivity to type I, but not type II pyrethroids. 
  • A strategy for the rapid identification of phosphorylation sites in the phosphoproteome. 
  • A structural basis for lithium and substrate binding of an inositide phosphatase. 
  • A structural pathway for activation of the kinesin motor ATPase. 
  • A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. 
  • A tactile response in Staphylococcus aureus. 
  • A unique phosphorylation-dependent mechanism for the activation of Ca2+/calmodulin-dependent protein kinase type IV/GR. 
  • ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients. 
  • AMH induces mesonephric cell migration in XX gonads. 
  • AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. 
  • ATM activation in normal human tissues and testicular cancer. 
  • Abl kinases regulate actin comet tail elongation via an N-WASP-dependent pathway. 
  • Absolute and relative truth in clinical trials. 
  • Absolute quantitation of endogenous proteins with precision and accuracy using a capillary Western system. 
  • Accelerated deamination of cytosine residues in UV-induced cyclobutane pyrimidine dimers leads to CC-->TT transitions. 
  • Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction. 
  • Acceleration of myosin light chain dephosphorylation and relaxation of smooth muscle by telokin. Synergism with cyclic nucleotide-activated kinase. 
  • Acetyl-CoA:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase is directly activated by p38 kinase. 
  • Acetylation of mitochondrial proteins. 
  • Activated alpha 2-macroglobulin promotes mitogenesis in rat vascular smooth muscle cells by a mechanism that is independent of growth-factor-carrier activity. 
  • Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. 
  • Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. 
  • Activation of EGF receptors mediates pulmonary vasoconstriction induced by residual oil fly ash. 
  • Activation of Gz attenuates Rap1-mediated differentiation of PC12 cells. 
  • Activation of direct and indirect pathways of glycogen synthesis by hepatic overexpression of protein targeting to glycogen. 
  • Activation of fibroblast growth factor (FGF) receptors by recombinant human FGF-5. 
  • Activation of four enzymes by two series of calmodulin mutants with point mutations in individual Ca2+ binding sites. 
  • Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. 
  • Activation of the cloned muscarinic potassium channel by G protein beta gamma subunits. 
  • Activation-dependent conformational changes in {beta}-arrestin 2. 
  • Activity and stability of recombinant bifunctional rearranged and monofunctional domains of ATP-sulfurylase and adenosine 5'-phosphosulfate kinase. 
  • Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. 
  • Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. 
  • Acute ischemic stroke treatment in 2007. 
  • Acyl-CoA thioesterase-2 facilitates mitochondrial fatty acid oxidation in the liver. 
  • Adding a positive charge at residue 46 of Drosophila alcohol dehydrogenase increases cofactor specificity for NADP+. 
  • Addressing cell-sourcing limitations with gene therapy. 
  • Adducin: a physical model with implications for function in assembly of spectrin-actin complexes. 
  • Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. 
  • Adenoviral expression of NHERF-1 in NHERF-1 null mouse renal proximal tubule cells restores Npt2a regulation by low phosphate media and parathyroid hormone. 
  • Adenovirus-mediated expression of the catalytic subunit of glucose-6-phosphatase in INS-1 cells. Effects on glucose cycling, glucose usage, and insulin secretion. 
  • Adenovirus-mediated overexpression of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in gluconeogenic rat hepatoma cells. Paradoxical effect on Fru-2,6-P2 levels. 
  • Adenovirus-mediated transfer of CCAAT/enhancer-binding protein-alpha identifies a dominant antiproliferative role for this isoform in hepatocytes. 
  • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. 
  • Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. 
  • Advances in Stroke 2017. 
  • Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. I. Physiology and biochemistry. 
  • Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. II. Morphometric analysis. 
  • Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. 
  • Allosteric activation of proto-oncogene kinase Src by GPCR-beta-arrestin complexes. 
  • Allosteric cooperation in a de novo-designed two-domain protein. 
  • Allosteric regulation of type I hexokinase: A site-directed mutational study indicating location of the functional glucose 6-phosphate binding site in the N-terminal half of the enzyme. 
  • Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. 
  • Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. 
  • Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease. 
  • American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. 
  • American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. 
  • Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function. 
  • Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. 
  • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 
  • An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model. 
  • An active site tyrosine influences the ability of the dimethyl sulfoxide reductase family of molybdopterin enzymes to reduce S-oxides. 
  • An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. 
  • An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. 
  • An approach to the study of G-protein-coupled receptor kinases: an in vitro-purified membrane assay reveals differential receptor specificity and regulation by G beta gamma subunits. 
  • An entirely cell-based system to generate single-chain antibodies against cell surface receptors. 
  • An important role of a pyrethroid-sensing residue F1519 in the action of the N-alkylamide insecticide BTG 502 on the cockroach sodium channel. 
  • An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. 
  • An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy. 
  • Anaemia of CKD--the CHOIR study revisited. 
  • Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. 
  • Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. 
  • Analysis of autoantibody binding to different regions of the human La antigen expressed in recombinant fusion proteins. 
  • Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. 
  • Analysis of functional domains of angiotensin II type 2 receptor involved in apoptosis. 
  • Analysis of recombinant Phex: an endopeptidase in search of a substrate. 
  • Analysis of site performance in academic-based and community-based centers in the IDEAL Study. 
  • Analysis of the kinetic mechanism of recombinant human isoprenylcysteine carboxylmethyltransferase (Icmt). 
  • Analysis of the molecular interaction of the farnesyl moiety of transducin through the use of a photoreactive farnesyl analogue. 
  • Andexanet Alfa Use in Cardiac Surgical Patients: A Xa Inhibitor and Heparin Reversal Agent. 
  • Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis? 
  • Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. 
  • Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. 
  • Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. 
  • Anemia and lung cancer. 
  • Anemia as a risk factor and therapeutic target in heart failure. 
  • Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. 
  • Angiotensin II type 2 receptor mediates programmed cell death. 
  • Anti-La antibody production by MRL-1pr/1pr mice. Analysis of fine specificity. 
  • Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). 
  • Antiangiogenic agents protect liver sinusoidal lining cells from cold preservation injury in rat liver transplantation. 
  • Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. 
  • Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. 
  • Antibody binding to a conformation-dependent epitope induces L-selectin association with the detergent-resistant cytoskeleton. 
  • Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. 
  • Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry. 
  • Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 
  • Anticoagulant therapy for percutaneous coronary intervention. 
  • Anticoagulant therapy in unstable angina. 
  • Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. 
  • Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. 
  • Antifibrotic and uveitogenic properties of gamma interferon in the rabbit eye. 
  • Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. 
  • Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? 
  • Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. 
  • Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. 
  • Antithrombin deficiency in special clinical syndromes--Part II: cardiovascular surgery. 
  • Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. 
  • Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. 
  • Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. 
  • Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. 
  • Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. 
  • Appearance of protease activities coincides with p10 and polyhedrin-driven protein production in the baculovirus expression system: effects on yield. 
  • Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. 
  • Aquaporins in Saccharomyces. Genetic and functional distinctions between laboratory and wild-type strains. 
  • Aquaporins in Saccharomyces: Characterization of a second functional water channel protein. 
  • Arachidonate and related unsaturated fatty acids selectively inactivate the guanine nucleotide-binding regulatory protein, Gz. 
  • Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. 
  • Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. 
  • Arsenic trioxide uptake by human and rat aquaglyceroporins. 
  • Assays for recombinant proteins: a problem in non-linear calibration. 
  • Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. 
  • Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. 
  • Astrocyte cytolysis by MHC class II-specific mouse T cell clones. 
  • Atomic distance estimates from disulfides and high-affinity metal-binding sites in a K+ channel pore. 
  • Atypical immunologic response in a patient with CRIM-negative Pompe disease. 
  • Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. 
  • Autoantibodies against cell surface GRP78 promote tumor growth in a murine model of melanoma. 
  • Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. 
  • Autoantibodies to DEK oncoprotein in human inflammatory disease. 
  • Autocrine stimulation of mas oncogene leads to altered growth control. 
  • Avid binding of beta A amyloid peptide to its own precursor. 
  • BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. 
  • BRCA2 monoclonal antibodies react with differentiating epithelium. 
  • Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin. 
  • Baculovirus expression of functional P210 BCR-ABL oncogene product. 
  • Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin. 
  • Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia. 
  • Bet v 1 and other birch allergens are more resistant to proteolysis and more abundant than other birch pollen proteins. 
  • Beta 2-adrenergic receptor stimulated, G protein-coupled receptor kinase 2 mediated, phosphorylation of ribosomal protein P2. 
  • Beta-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. 
  • Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. 
  • Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. 
  • Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. 
  • Bimatoprost, prostamide activity, and conventional drainage. 
  • Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding. 
  • Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. 
  • Binding site for C4b-binding protein in vitamin K-dependent protein S fully contained in carboxy-terminal laminin-G-type repeats. A study using recombinant factor IX-protein S chimeras and surface plasmon resonance. 
  • Biochemical analysis of inositol phosphate kinases. 
  • Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. 
  • Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. 
  • Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring. 
  • Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. 
  • Biosynthesis of undecaprenyl phosphate-galactosamine and undecaprenyl phosphate-glucose in Francisella novicida. 
  • Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. 
  • Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. 
  • Bivalirudin for patients with acute coronary syndromes. 
  • Bivalirudin in off-pump coronary artery bypass graft in a patient with heparin-induced thrombocytopenia: a case report of its use. 
  • Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. 
  • Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. 
  • Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial. 
  • Bivalirudin: a review of the pharmacology and clinical application. 
  • Bleeding and management of coagulopathy. 
  • Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. 
  • Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells. 
  • Boceprevir for HCV in patients with HIV: where next? 
  • Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. 
  • Boceprevir for untreated chronic HCV genotype 1 infection. 
  • Bone morphogenetic protein 4 mediates myocardial ischemic injury through JNK-dependent signaling pathway. 
  • Bone morphogenetic protein induces bone in the squirrel monkey, but bone matrix does not. 
  • Bone morphogenetic protein-4 (BMP-4) acts during gastrula stages to cause ventralization of Xenopus embryos. 
  • Bone sialoprotein-collagen interaction promotes hydroxyapatite nucleation. 
  • Bovine thrombin: history, use, and risk in the surgical patient. 
  • C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. 
  • C-terminally truncated derivatives of Escherichia coli Hfq are proficient in riboregulation. 
  • C3orf58, a novel paracrine protein, stimulates cardiomyocyte cell-cycle progression through the PI3K-AKT-CDK7 pathway. 
  • CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. 
  • CD4 binding to major histocompatibility complex class II antigens induces LFA-1-dependent and -independent homotypic adhesion of B lymphocytes. 
  • CD4 mimetics sensitize HIV-1-infected cells to ADCC. 
  • CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. 
  • CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. 
  • CDK5 regulates cell adhesion and migration in corneal epithelial cells. 
  • COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors. 
  • CTL cross reactivity between HIV strains. 
  • Ca2+-sensitive inactivation and facilitation of L-type Ca2+ channels both depend on specific amino acid residues in a consensus calmodulin-binding motif in the(alpha)1C subunit. 
  • Cadherin-11 expressed in association with mesenchymal morphogenesis in the head, somite, and limb bud of early mouse embryos. 
  • Calcineurin mutants render T lymphocytes resistant to cyclosporin A. 
  • Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression. 
  • Calibration inference based on multiple runs of an immunoassay. 
  • Calmodulin activation of target enzymes. Consequences of deletions in the central helix. 
  • Calmodulin mediates Ca2+ sensitivity of sodium channels. 
  • Calmodulin structure refined at 1.7 A resolution. 
  • Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. 
  • Cardiac myocyte p38α kinase regulates angiogenesis via myocyte-endothelial cell cross-talk during stress-induced remodeling in the heart. 
  • Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. 
  • Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. 
  • Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex. 
  • Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. 
  • Cell adhesion molecule L1 in folded (horseshoe) and extended conformations. 
  • Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells. 
  • Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. 
  • Cell- and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins. 
  • Cell-dependent posttranslational processing and secretion of recombinant mouse renin-2. 
  • Cell-mediated cytotoxicity of murine cytomegalovirus-infected target cells allows for release of residual infectious virus. 
  • Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. 
  • Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. 
  • Cellular crosstalk regulates the aqueous humor outflow pathway and provides new targets for glaucoma therapies. 
  • Challenges for providing effective hemostasis in surgery and trauma. 
  • Characterisation of PduS, the pdu metabolosome corrin reductase, and evidence of substructural organisation within the bacterial microcompartment. 
  • Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. 
  • Characterization of Leu777Pro and Ile865Thr type IIA von Willebrand disease mutations. 
  • Characterization of a Drosophila U snRNP RNA-binding protein. 
  • Characterization of a monoclonal antibody specific for human active renin. 
  • Characterization of a new family of protein kinases from Arabidopsis containing phosphoinositide 3/4-kinase and ubiquitin-like domains. 
  • Characterization of a protein cofactor that mediates protein kinase A regulation of the renal brush border membrane Na(+)-H+ exchanger. 
  • Characterization of a rat type 2 angiotensin II receptor stably expressed in 293 cells. 
  • Characterization of a trimeric MPER containing HIV-1 gp41 antigen. 
  • Characterization of alpha 2-macroglobulin binding to human trabecular meshwork cells: presence of the alpha 2-macroglobulin signaling receptor. 
  • Characterization of alpha-1 adrenoceptor subtypes in human and canine prostate membranes. 
  • Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity. 
  • Characterization of an iron-sulfur cluster assembly protein (ISU1) from Schizosaccharomyces pombe. 
  • Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. 
  • Characterization of avian and viral p60src proteins expressed in yeast. 
  • Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. 
  • Characterization of elongation factor-1A (eEF1A-1) and eEF1A-2/S1 protein expression in normal and wasted mice. 
  • Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR. 
  • Characterization of key residues in the subdomain encoded by exons 8 and 9 of human inducible nitric oxide synthase: a critical role for Asp-280 in substrate binding and subunit interactions. 
  • Characterization of kinectin, a kinesin-binding protein: primary sequence and N-terminal topogenic signal analysis. 
  • Characterization of moesin in the sea urchin Lytechinus variegatus: redistribution to the plasma membrane following fertilization is inhibited by cytochalasin B. 
  • Characterization of prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells. 
  • Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants. 
  • Characterization of turkey inducible nitric oxide synthase and identification of its expression in the intestinal epithelium following astrovirus infection. 
  • Characterizing the use of perdeuteration in NMR studies of large proteins: 13C, 15N and 1H assignments of human carbonic anhydrase II. 
  • Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chicken progesterone receptor expressed in Saccharomyces cerevisiae is correctly phosphorylated at all four Ser-Pro phosphorylation sites. 
  • Chromosome 19 microRNAs exert antiviral activity independent from type III interferon signaling. 
  • Ciliary neurotrophic factor is an axogenesis factor for retinal ganglion cells. 
  • Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. 
  • Clearance and distribution of recombinant murine gamma-interferon in mice. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. 
  • Clinical and economic lessons from studies of coronary thrombolysis. 
  • Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. 
  • Clinical benefits of pegylated proteins in oncology. 
  • Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. 
  • Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). 
  • Clinical outcomes of bivalirudin for ischemic heart disease. 
  • Clinical practice. Heparin-induced thrombocytopenia. 
  • Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. 
  • Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. 
  • Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. 
  • Clinical uses of pegylated pharmaceuticals in oncology. 
  • Cloned Erwinia chrysanthemi out genes enable Escherichia coli to selectively secrete a diverse family of heterologous proteins to its milieu. 
  • Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. 
  • Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. 
  • Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. 
  • Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei. 
  • Cloning and characterization of a mammalian prenyl protein-specific protease. 
  • Cloning and characterization of two human VIP1-like inositol hexakisphosphate and diphosphoinositol pentakisphosphate kinases. 
  • Cloning and expression of full-length cDNA encoding human vitamin D receptor. 
  • Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. 
  • Cloning, expression, and cellular localization of a human prenylcysteine lyase. 
  • Cloning, sequencing, and recombinant expression of the porcine inhibitor of carbonic anhydrase: a novel member of the transferrin family. 
  • Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. 
  • Coagulopathy and inflammation in neonatal heart surgery: mechanisms and strategies. 
  • Colony-stimulating factor use in the context of refined risk and benefit assessments. 
  • Combinatorial codon scrambling enables scalable gene synthesis and amplification of repetitive proteins. 
  • Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. 
  • Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. 
  • Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. 
  • Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. 
  • Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. 
  • Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis. 
  • Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. 
  • Comparison of the effects of IL-1 alpha and TNF-alpha on phagocyte accumulation and murine antibacterial immunity. 
  • Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE. 
  • Comparison of the role of esterases in the differential age-related sensitivity to chlorpyrifos and methamidophos. 
  • Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. 
  • Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). 
  • Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria. 
  • Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. 
  • Components of a calmodulin-dependent protein kinase cascade. Molecular cloning, functional characterization and cellular localization of Ca2+/calmodulin-dependent protein kinase kinase beta. 
  • Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5. 
  • Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase. 
  • Conformational changes in the photocycle of Anabaena sensory rhodopsin: absence of the Schiff base counterion protonation signal. 
  • Conformational changes of purine repressor DNA-binding domain upon complexation with DNA. 
  • Conjunctival intraepithelial neoplasia. 
  • Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. 
  • Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. 
  • Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. 
  • Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. 
  • Contrasting response of lung parenchymal cells to instilled TNF alpha and IFN gamma: the inducibility of specific cell ICAM-1 in vivo. 
  • Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. 
  • Control of protein-ligand recognition using a stimuli-responsive polymer. 
  • Conversion of Bcl-2 to a Bax-like death effector by caspases. 
  • Conversion of Tyr361 beta to Leu in mammalian protein farnesyltransferase impairs product release but not substrate recognition. 
  • Cooperation between core binding factor and adjacent promoter elements contributes to the tissue-specific expression of interleukin-3. 
  • Cooperative interaction of divalent metal ions, substrate, and tissue factor with factor VIIa. 
  • Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. 
  • Correction of anemia with epoetin alfa in chronic kidney disease. 
  • Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. 
  • Cost-Utility Analysis of rhBMP-2 Use in Adult Spinal Deformity Surgery. 
  • Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. 
  • Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. 
  • Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. 
  • Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. 
  • Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. 
  • Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. 
  • Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. 
  • Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. 
  • Critical factors in basal cell adhesion molecule/lutheran-mediated adhesion to laminin. 
  • Cross-desensitization of chemoattractant receptors occurs at multiple levels. Evidence for a role for inhibition of phospholipase C activity. 
  • Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. 
  • Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. 
  • Crystal structure of a thermostable Bacillus DNA polymerase I large fragment at 2.1 A resolution. 
  • Crystal structure of activated CheY. Comparison with other activated receiver domains. 
  • Crystal structure of inositol polyphosphate 1-phosphatase at 2.3-A resolution. 
  • Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. 
  • Crystal structure of the ternary complex of a NaV C-terminal domain, a fibroblast growth factor homologous factor, and calmodulin. 
  • Crystal structure of the transcription activator BmrR bound to DNA and a drug. 
  • Crystallization and initial X-ray crystallographic characterization of recombinant bovine inositol polyphosphate 1-phosphatase produced in Spodoptera frugiperda cells. 
  • Crystallization and preliminary x-ray studies of NADPH-cytochrome P450 reductase. 
  • Crystallization of a Complex Between MYC and Jas Motif. 
  • Current concepts in the management of central retinal vein occlusion. 
  • Current insights on the biology and clinical aspects of VEGF regulation. 
  • Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 
  • Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients. 
  • Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. 
  • Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. 
  • Cytokine signals through STAT3 promote expression of granulocyte secondary granule proteins in 32D cells. 
  • Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. 
  • Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. 
  • Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. 
  • DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. 
  • DNA CpG methylation inhibits binding of NF-kappa B proteins to the HIV-1 long terminal repeat cognate DNA motifs. 
  • DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. 
  • DNA repair protein O6-alkylguanine-DNA alkyltransferase is phosphorylated by two distinct and novel protein kinases in human brain tumour cells. 
  • DRIVE it home: making the case for prospective economic data collection in randomized clinical trials. 
  • Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. 
  • De novo design, expression, and characterization of Felix: a four-helix bundle protein of native-like sequence. 
  • De novo engineering of intracellular condensates using artificial disordered proteins. 
  • Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. 
  • Defining G protein beta gamma specificity for effector recognition. 
  • Defining fibronectin's cell adhesion synergy site by site-directed mutagenesis. 
  • Definition and management of anemia in patients infected with hepatitis C virus. 
  • Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain. 
  • Deletion and site-directed mutagenesis of the ATP-binding motif (P-loop) in the bifunctional murine ATP-sulfurylase/adenosine 5'-phosphosulfate kinase enzyme. 
  • Deletion of carboxy-terminal residues of murine granulocyte-macrophage colony-stimulating factor results in a loss of biologic activity and altered glycosylation. 
  • Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. 
  • Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response. 
  • Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. 
  • Design of a novel small peptide targeted against a tumor-specific receptor. 
  • Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). 
  • Design of the RELAXin in acute heart failure study. 
  • Design of thermally responsive, recombinant polypeptide carriers for targeted drug delivery. 
  • Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. 
  • Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. 
  • Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network. 
  • Determinants of Tenascin-C and HIV-1 envelope binding and neutralization. 
  • Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. 
  • Determinants of backbone dynamics in native BPTI: cooperative influence of the 14-38 disulfide and the Tyr35 side-chain. 
  • Development and cardiac contractility: cardiac troponin T isoforms and cytosolic calcium in rabbit. 
  • Development of a serological test for Haemophilus ducreyi for seroprevalence studies. 
  • Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. 
  • Development of novel tumor imaging agents with phage-display combinatorial peptide libraries. 
  • Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. 
  • Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. 
  • Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. 
  • Diagnosis and management of conjunctival and corneal intraepithelial neoplasia using ultra high-resolution optical coherence tomography. 
  • Diagnosis and treatment of chronic hepatitis C infection. 
  • Differences in Methadone Metabolism by CYP2B6 Variants. 
  • Different dimerization activities of alpha and beta thyroid hormone receptor isoforms. 
  • Different oligomeric forms of protein phosphatase 2A activate and inhibit simian virus 40 DNA replication. 
  • Different structural changes occur in blue- and green-proteorhodopsins during the primary photoreaction. 
  • Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies. 
  • Differential activation of nitric-oxide synthase isozymes by calmodulin-troponin C chimeras. 
  • Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2. Evidence for time-dependent signal generation. 
  • Differential desensitization and phosphorylation of three cloned and transfected alpha 2-adrenergic receptor subtypes. 
  • Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling. 
  • Differential effects of nitric oxide-mediated S-nitrosylation on p50 and c-jun DNA binding. 
  • Differential metabolic effects of adenovirus-mediated glucokinase and hexokinase I overexpression in rat primary hepatocytes. 
  • Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases. 
  • Differential regulation of transcription: repression by unactivated mitogen-activated protein kinase Kss1 requires the Dig1 and Dig2 proteins. 
  • Dihydrophenylalanine: a prephenate-derived Photorhabdus luminescens antibiotic and intermediate in dihydrostilbene biosynthesis. 
  • Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). 
  • Direct interactions between corepressors and coactivators permit the integration of nuclear receptor-mediated repression and activation. 
  • Direct oral anticoagulants: a review on the current role and scope of reversal agents. 
  • Direct thrombin inhibitors: alternatives to heparin. 
  • Direct-contact co-culture between smooth muscle and endothelial cells inhibits TNF-alpha-mediated endothelial cell activation. 
  • Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Discontinuation and management of direct-acting anticoagulants for emergency procedures. 
  • Discrete and complementary mechanisms of protection of beta-cells against cytokine-induced and oxidative damage achieved by bcl-2 overexpression and a cytokine selection strategy. 
  • Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography. 
  • Display of cell surface sites for fibronectin assembly is modulated by cell adherence to (1)F3 and C-terminal modules of fibronectin. 
  • Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity. 
  • Distinguishing mechanisms from markers of cardiac contractile dysfunction: more than 1 way to skin the cat of heart failure. 
  • Does recombinant human bone morphogenetic protein-2 use in adult spinal deformity increase complications and are complications associated with location of rhBMP-2 use? A prospective, multicenter study of 279 consecutive patients. 
  • Domain-specific antibodies reveal multiple-site topology of Nup153 within the nuclear pore complex. 
  • Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. 
  • Dose escalation trial of cyclophosphamide with Sargramostim in the treatment of central nervous system (CNS) neoplasms. 
  • Dose response of angiogenesis to basic fibroblast growth factor in rat corneal pocket assay: I. Experimental characterizations. 
  • Dose response of angiogenesis to basic fibroblast growth factor in rat corneal pocket assay: II. Numerical simulations. 
  • Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. 
  • Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. 
  • Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. 
  • Drosophila spectrin. II. Conserved features of the alpha-subunit are revealed by analysis of cDNA clones and fusion proteins. 
  • Drotrecogin alfa (activated) in adults with septic shock. 
  • Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. 
  • Dual kinase-mediated regulation of PITK by CaMKII and GSK3. 
  • Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. 
  • Dusp3 and Psme3 are associated with murine susceptibility to Staphylococcus aureus infection and human sepsis. 
  • Dynamics of the epigenetic landscape during erythroid differentiation after GATA1 restoration. 
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 
  • Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease. 
  • E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma. 
  • ELAV proteins stabilize deadenylated intermediates in a novel in vitro mRNA deadenylation/degradation system. 
  • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. 
  • Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery. 
  • Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. 
  • Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. 
  • Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. 
  • Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. 
  • Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. 
  • Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. 
  • Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. 
  • Economic impact of new interventional therapies: are we asking the right questions? 
  • Editorial: Recombinant human bone morphogenetic protein-2. 
  • Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. 
  • Effect of Mts1 on the structure and activity of nonmuscle myosin II. 
  • Effect of basic fibroblast growth factor on angiogenesis and growth of isografted bone: quantitative in vitro-in vivo analysis in mice. 
  • Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). 
  • Effect of combined anticoagulation using heparin and bivalirudin on the hemostatic and inflammatory responses to cardiopulmonary bypass in the rat. 
  • Effect of cysteine residues on the activity of arginyl-tRNA synthetase from Escherichia coli. 
  • Effect of genetic circular permutation near the active site on the activity and stability of an enzyme inhibitor. 
  • Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. 
  • Effect of heterologous factor V heavy chain sequences on the secretion of recombinant human factor VIII. 
  • Effect of intraocular gamma-interferon on immunoregulatory properties of iris and ciliary body cells. 
  • Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots. 
  • Effect of modified ultrafiltration on bivalirudin elimination and postoperative blood loss after on-pump coronary artery bypass grafting: assessment of different filtration strategies. 
  • Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. 
  • Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. 
  • Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. 
  • Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. 
  • Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. 
  • Effect of streptavidin RGD mutant on the adhesion of endothelial cells. 
  • Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. 
  • Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. 
  • Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. 
  • Effects of Serelaxin in Patients with Acute Heart Failure. 
  • Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of growth hormone and IGF-I on cardiac hypertrophy and gene expression in mice. 
  • Effects of hematopoietic growth factors following myeloablation in a primate model. 
  • Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model. 
  • Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates. 
  • Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. 
  • Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. 
  • Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. 
  • Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. 
  • Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. 
  • Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. 
  • Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. 
  • Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy. 
  • Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. 
  • Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. 
  • Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. 
  • Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. 
  • Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. 
  • Efficacy of recombinant human manganese superoxide dismutase compared to allopurinol in protection of ischemic skeletal muscle against "no-reflow". 
  • Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. 
  • Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study. 
  • Electrocardiographic response to enzyme replacement therapy for Pompe disease. 
  • Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis. 
  • Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux. 
  • Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. 
  • Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. 
  • Elimination of antibodies to recombinant enzyme in Pompe's disease. 
  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. 
  • Emergent bistability by a growth-modulating positive feedback circuit. 
  • Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC. 
  • Endonucleolytic function of MutLalpha in human mismatch repair. 
  • Engineered Ribonucleoprotein Granules Inhibit Translation in Protocells. 
  • Engineered leucine zippers show that hemiphosphorylated CREB complexes are transcriptionally active. 
  • Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells. 
  • Engineering of glucose-stimulated insulin secretion and biosynthesis in non-islet cells. 
  • Engineering soluble major histocompatibility molecules: why and how. 
  • Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. 
  • Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. 
  • Enhanced HIV-1 activity in bone marrow can lead to myelopoietic suppression partially contributed by gag p24. 
  • Enhanced TOF-SIMS imaging of a micropatterned protein by stable isotope protein labeling. 
  • Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model. 
  • Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. 
  • Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. 
  • Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. 
  • Enrichment of peripheral blood stem cells in a primate model following administration of a single dose of rh-IL-1 beta. 
  • Enzymatic modification of proteins with a geranylgeranyl isoprenoid. 
  • Enzymatic properties of ALDH1L2, a mitochondrial 10-formyltetrahydrofolate dehydrogenase. 
  • Enzymatically inactive p60c-src mutant with altered ATP-binding site is fully phosphorylated in its carboxy-terminal regulatory region. 
  • Epidermal growth factor augments adaptation following small bowel resection: optimal dosage, route, and timing of administration. 
  • Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. 
  • Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. 
  • Erythropoietin Stimulates Tumor Growth via EphB4. 
  • Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart. 
  • Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. 
  • Erythropoietin biology in cancer. 
  • Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. 
  • Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. 
  • Erythropoietin receptor contributes to melanoma cell survival in vivo. 
  • Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. 
  • Erythropoietin: high profile, high scrutiny. 
  • Escherichia coli purine repressor: key residues for the allosteric transition between active and inactive conformations and for interdomain signaling. 
  • Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. 
  • Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. 
  • Eukaryotic transcription termination factor La mediates transcript release and facilitates reinitiation by RNA polymerase III. 
  • Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. 
  • Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. 
  • Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. 
  • Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia. 
  • Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke. 
  • Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential. 
  • Evidence for a catalytic role of zinc in protein farnesyltransferase. Spectroscopy of Co2+-farnesyltransferase indicates metal coordination of the substrate thiolate. 
  • Evidence for a novel insulin-like growth factor (IGF)-dependent protease regulating IGF-binding protein-4 in dermal fibroblasts. 
  • Evidence for an alternative glycolytic pathway in rapidly proliferating cells. 
  • Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. 
  • Evidence of Fe3+ interaction with the plug domain of the outer membrane transferrin receptor protein of Neisseria gonorrhoeae: implications for Fe transport. 
  • Evolution of a tumorigenic property conferred by glycophosphatidyl-inositol membrane anchors of carcinoembryonic antigen gene family members during the primate radiation. 
  • Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. 
  • Exogenous Hsp70 delays senescence and improves cognitive function in aging mice. 
  • Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention--an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. 
  • Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region. 
  • Expression and modulation of RPE cell membrane complement regulatory proteins. 
  • Expression and site-directed mutagenesis of the phosphatidylcholine-preferring phospholipase C of Bacillus cereus: probing the role of the active site Glu146. 
  • Expression cloning of TGF-beta receptors. 
  • Expression in Escherichia coli of the thermostable DNA polymerase from Pyrococcus furiosus. 
  • Expression of a bacterial catalase in a strictly anaerobic methanogen significantly increases tolerance to hydrogen peroxide but not oxygen. 
  • Expression of aquaporin-1 in human trabecular meshwork cells: role in resting cell volume. 
  • Expression of exogenous protein in the egg white of transgenic chickens. 
  • Expression of functional bacterial undecaprenyl pyrophosphate synthase in the yeast rer2{Delta} mutant and CHO cells. 
  • Expression of functional chicken oviduct progesterone receptors in yeast (Saccharomyces cerevisiae). 
  • Expression of glucokinase in cultured human muscle cells confers insulin-independent and glucose concentration-dependent increases in glucose disposal and storage. 
  • Expression of human vitamin D receptor in Saccharomyces cerevisiae. Purification, properties, and generation of polyclonal antibodies. 
  • Expression of recombinant human methylmalonyl-CoA mutase: in primary mut fibroblasts and Saccharomyces cerevisiae. 
  • Expression of the CD7 ligand K-12 in human thymic epithelial cells: regulation by IFN-gamma. 
  • Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression. 
  • Expression of three forms of melanoma growth stimulating activity (MGSA)/gro in human retinal pigment epithelial cells. 
  • Expression, purification, and in vitro assays of mitochondrial single-stranded DNA-binding protein. 
  • Expression, purification, crystallization and preliminary X-ray analysis of human argininosuccinic acid lyase. 
  • Expression, subcellular localization, and enzyme activity of a recombinant human extra-cellular superoxide dismutase in tobacco (Nicotiana benthamiana L.). 
  • Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. 
  • Extracellular secretion of pectate lyase by the Erwinia chrysanthemi out pathway is dependent upon Sec-mediated export across the inner membrane. 
  • Extracellular trafficking of myocilin in human trabecular meshwork cells. 
  • FGF23 induces left ventricular hypertrophy. 
  • Facilitated PCI in patients with ST-elevation myocardial infarction. 
  • Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. 
  • Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. 
  • Factor VIIa for Annulus Rupture After Transcatheter Aortic Valve Replacement. 
  • Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I. 
  • Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. 
  • Fibroblast growth factor 21 mediates specific glucagon actions. 
  • Filgrastim in patients with neutropenia: potential effects on quality of life. 
  • FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. 
  • Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. 
  • Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. 
  • Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. 
  • Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. 
  • Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. 
  • Fluorescent probes as indicators of conformation changes in transducin on activation. 
  • Food safety. Lead, pesticides, antibiotics, hormones, and irradiation. 
  • Force measurements of the alpha5beta1 integrin-fibronectin interaction. 
  • Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta. 
  • Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). 
  • Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Frequency-specific association of antibodies against heat shock proteins 60 and 70 with noise-induced hearing loss in Chinese workers. 
  • FtsZ from divergent foreign bacteria can function for cell division in Escherichia coli. 
  • Functional Assessment of the Efficacy of Oxygen Free Radical Scavengers in the "No-Reflow" Phenomenon in Skeletal Muscle. 
  • Functional Class I and II Amino Acid-activating Enzymes Can Be Coded by Opposite Strands of the Same Gene. 
  • Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets. 
  • Functional characterization of medaka CYP3A38 and CYP3A40: kinetics and catalysis by expression in a recombinant baculovirus system. 
  • Functional domains of the human vitamin D3 receptor regulate osteocalcin gene expression. 
  • Functional equivalence of an evolutionarily conserved RNA binding module. 
  • Functional expression of the multidrug resistance-associated protein in the yeast Saccharomyces cerevisiae. 
  • Functional interactions of recombinant alpha 2 adrenergic receptor subtypes and G proteins in reconstituted phospholipid vesicles. 
  • Functional reconstitution of purified human Hv1 H+ channels. 
  • Functional selection of protease inhibitory antibodies. 
  • Future trends in managing hepatitis C. 
  • G protein beta gamma subunits from bovine brain and retina: equivalent catalytic support of ADP-ribosylation of alpha subunits by pertussis toxin but differential interactions with Gs alpha. 
  • G protein beta gamma subunits stimulate phosphorylation of Shc adapter protein. 
  • G protein signaling and vein graft intimal hyperplasia: reduction of intimal hyperplasia in vein grafts by a Gbetagamma inhibitor suggests a major role of G protein signaling in lesion development. 
  • G(o)-protein alpha-subunits activate mitogen-activated protein kinase via a novel protein kinase C-dependent mechanism. 
  • G4 resolvase 1 binds both DNA and RNA tetramolecular quadruplex with high affinity and is the major source of tetramolecular quadruplex G4-DNA and G4-RNA resolving activity in HeLa cell lysates. 
  • GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. 
  • Galpha12 and Galpha13 negatively regulate the adhesive functions of cadherin. 
  • Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Gene deletion screen for cardiomyopathy in adult Drosophila identifies a new notch ligand. 
  • Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. 
  • Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. 
  • Gene targeting of a CFTR allele in HT29 human epithelial cells. 
  • Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. 
  • Generation of recombinant vaccinia virus and analysis of virus-induced cell death. 
  • Generation of reovirus core-like particles in cells infected with hybrid vaccinia viruses that express genome segments L1, L2, L3, and S2. 
  • Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. 
  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 
  • Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. 
  • Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase. 
  • Glutamate 350 Plays an Essential Role in Conformational Gating of Long-Range Radical Transport in Escherichia coli Class Ia Ribonucleotide Reductase. 
  • Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. 
  • Glycosylated recombinant human XCL1/lymphotactin exhibits enhanced biologic activity. 
  • Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. 
  • Gq-dependent signaling upregulates COX2 in glomerular podocytes. 
  • Granulocyte colony-stimulating factors: finding the right indication. 
  • Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. 
  • Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. 
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. 
  • Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells. 
  • Granulocyte-macrophage colony-stimulating factor primes neutrophils by activating a pertussis toxin-sensitive G protein not associated with phosphatidylinositol turnover. 
  • Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. 
  • Grc3 programs the essential endoribonuclease Las1 for specific RNA cleavage. 
  • Growth arrest and DNA damage-inducible protein GADD34 assembles a novel signaling complex containing protein phosphatase 1 and inhibitor 1. 
  • Growth arrest and DNA damage-inducible protein GADD34 targets protein phosphatase 1 alpha to the endoplasmic reticulum and promotes dephosphorylation of the alpha subunit of eukaryotic translation initiation factor 2. 
  • Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. 
  • Growth factors for therapeutic angiogenesis in peripheral arterial disease. 
  • Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates. 
  • Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. 
  • Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. 
  • Gz, a guanine nucleotide-binding protein with unique biochemical properties. 
  • H(2)O(2)-induced O(2) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. 
  • H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. 
  • HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. 
  • HDAC6 modulates cell motility by altering the acetylation level of cortactin. 
  • HIV envelope gp120 activates human arterial smooth muscle cells. 
  • HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. 
  • HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. 
  • HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity. 
  • HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. 
  • HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). 
  • HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. 
  • Haem oxygenase-1 prevents cell death by regulating cellular iron. 
  • Haemostasis: from bench to bedside. 
  • Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. 
  • Heart failure with preserved ejection fraction in the elderly: scope of the problem. 
  • Heat and cold denatured states of monomeric lambda repressor are thermodynamically and conformationally equivalent. 
  • Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. 
  • Hel-N1: an autoimmune RNA-binding protein with specificity for 3' uridylate-rich untranslated regions of growth factor mRNAs. 
  • Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. 
  • Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. 
  • Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. 
  • Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. 
  • Heparin neutralization by recombinant platelet factor 4 and protamine. 
  • Heparin-induced thrombocytopenia and cardiac surgery. 
  • Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. 
  • Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. 
  • Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. 
  • Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. 
  • Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. 
  • Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. 
  • Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5. 
  • Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. 
  • Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. 
  • Heuristics for the Optimal Presentation of Bioactive Peptides on Polypeptide Micelles. 
  • High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. 
  • High dose factor VIIa improves clot structure and stability in a model of haemophilia B. 
  • High level expression of mammalian protein farnesyltransferase in a baculovirus system. The purified protein contains zinc. 
  • High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates. 
  • High resolution AFM topographs of the Escherichia coli water channel aquaporin Z. 
  • High-dose aprotinin effectively reduces blood loss during on-pump coronary artery bypass grafting with bivalirudin anticoagulation. 
  • High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. 
  • High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. 
  • High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support. 
  • High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. 
  • High-level expression and single-step purification of leucyl-tRNA synthetase from Escherichia coli. 
  • High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. 
  • High-level synthesis of biologically active reovirus protein sigma 1 in a mammalian expression vector system. 
  • Home surveillance program prevents interstage mortality after the Norwood procedure. 
  • Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. 
  • Hospital variability in use of anticoagulant strategies during acute myocardial infarction treated with an early invasive strategy. 
  • Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. 
  • Human IL-1 beta processing and secretion in recombinant baculovirus-infected Sf9 cells is blocked by the cowpox virus serpin crmA. 
  • Human alveolar and peritoneal macrophages mediate fungistasis independently of L-arginine oxidation to nitrite or nitrate. 
  • Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. 
  • Human apolipoprotein B transgenic mice generated with 207- and 145-kilobase pair bacterial artificial chromosomes. Evidence that a distant 5'-element confers appropriate transgene expression in the intestine. 
  • Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner. 
  • Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. 
  • Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. 
  • Human exonuclease I is required for 5' and 3' mismatch repair. 
  • Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. 
  • Human interleukin-2 production in insect (Trichoplusia ni) larvae: effects and partial control of proteolysis. 
  • Human placental lactogen infusions into the medial preoptic area stimulate maternal behavior in steroid-primed, nulliparous female rats. 
  • Human protein phosphatase PP6 regulatory subunits provide Sit4-dependent and rapamycin-sensitive sap function in Saccharomyces cerevisiae. 
  • Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. 
  • Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. 
  • Human recombinant interleukin-1 alpha increases elastase-like enzyme in human uterine cervical fibroblasts. 
  • Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients. 
  • Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. 
  • Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein. 
  • Human substance P receptor expressed in Chinese hamster ovary cells directly activates G(alpha q/11), G(alpha s), G(alpha o). 
  • Human substance P receptor expressed in Sf9 cells couples with multiple endogenous G proteins. 
  • Human sulfite oxidase R160Q: identification of the mutation in a sulfite oxidase-deficient patient and expression and characterization of the mutant enzyme. 
  • Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II. 
  • Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. 
  • Hypercholesterolemia in rats with chronic renal insufficiency not aggravated by recombinant human growth hormone. 
  • Hyperimmune human IgG or recombinant human granulocyte-macrophage colony-stimulating factor as adjunctive therapy for group B streptococcal sepsis in newborn rats. 
  • Hyperphosphorylated C-terminal repeat domain-associating proteins in the nuclear proteome link transcription to DNA/chromatin modification and RNA processing. 
  • Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. 
  • Hypoxia modulates nitric oxide-induced regulation of NMDA receptor currents and neuronal cell death. 
  • Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. 
  • IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. 
  • IL-1 beta induces COX2, MMP-1, -3 and -13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. 
  • IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. 
  • IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). 
  • IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • INITIAL ADOPTION OF RECOMBINANT HUMAN THYROID-STIMULATING HORMONE FOLLOWING THYROIDECTOMY IN THE MEDICARE THYROID CANCER PATIENT POPULATION. 
  • Identification and biochemical studies on novel non-nucleoside inhibitors of the enzyme adenosine kinase. 
  • Identification and characterization of a Drosophila nuclear receptor with the ability to inhibit the ecdysone response. 
  • Identification and characterization of a cDNA encoding cytochrome P450 3A from the fresh water teleost medaka (Oryzias latipes). 
  • Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. 
  • Identification and characterization of the sodium-binding site of activated protein C. 
  • Identification and characterization of two Ca2+/CaM-dependent protein kinases required for normal nuclear division in Aspergillus nidulans. 
  • Identification of NSF as a beta-arrestin1-binding protein. Implications for beta2-adrenergic receptor regulation. 
  • Identification of a negative regulatory function for steroid receptors. 
  • Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. 
  • Identification of amino acid residues involved in structural and ubiquinone-binding functions of subunit IV of the cytochrome bc1 complex from Rhodobacter sphaeroides. 
  • Identification of amino acid sequences in fibrinogen gamma -chain and tenascin C C-terminal domains critical for binding to integrin alpha vbeta 3. 
  • Identification of amino acids essential for calmodulin binding and activation of smooth muscle myosin light chain kinase. 
  • Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate. 
  • Identification of an estrogen response element in the 3'-flanking region of the murine c-fos protooncogene. 
  • Identification of quinone-binding and heme-ligating residues of the smallest membrane-anchoring subunit (QPs3) of bovine heart mitochondrial succinate:ubiquinone reductase. 
  • Identification of recombinant antibodies against multiple distinct toll-like receptors by homolog mining a single immune scFv phage library. 
  • Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. 
  • Identification of the G protein-coupled receptor kinase phosphorylation sites in the human beta2-adrenergic receptor. 
  • Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. 
  • Identification of two regions of beta G spectrin that bind to distinct sites in brain membranes. 
  • Identification of ubiquitination sites on the X-linked inhibitor of apoptosis protein. 
  • Identification, cloning, and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1. 
  • IgG autoantibodies to "switch peptide" determinants of TCR alpha/beta in human pregnancy. 
  • Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment. 
  • Immediate Effects of Use of Recombinant Bone Morphogenetic Protein in Children Having Spinal Fusion and Refusion Procedures in United States. 
  • Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye. 
  • Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. 
  • Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). 
  • Immunoaffinity purification of epitope-tagged human beta 2-adrenergic receptor to homogeneity. 
  • Immunochemical proof that a novel rearranging gene encodes the T cell receptor delta subunit. 
  • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. 
  • Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. 
  • Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. 
  • Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. 
  • Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. 
  • Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. 
  • Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. 
  • Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. 
  • Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. 
  • Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. 
  • Impact of a cryopreservation program on the multiple pregnancy rate associated with assisted reproductive technologies. 
  • Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. 
  • Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. 
  • Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). 
  • Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group. 
  • Implications for proteasome nuclear localization revealed by the structure of the nuclear proteasome tether protein Cut8. 
  • Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. 
  • Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). 
  • Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease. 
  • Improving the management of chemotherapy-induced neutropenia. 
  • In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. 
  • In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. 
  • In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. 
  • In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. 
  • In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition. 
  • In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. 
  • In vitro incorporation of nascent molybdenum cofactor into human sulfite oxidase. 
  • In vitro motility of AtKCBP, a calmodulin-binding kinesin protein of Arabidopsis. 
  • In vitro processing of recombinant G protein gamma subunits. Requirements for assembly of an active beta gamma complex. 
  • In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations. 
  • In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function. 
  • In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. 
  • Inactivation of LRG-47 and IRG-47 reveals a family of interferon gamma-inducible genes with essential, pathogen-specific roles in resistance to infection. 
  • Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. 
  • Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. 
  • Increased interleukin 1 beta in human skeletal muscle after exercise. 
  • Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. 
  • Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. 
  • Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate. 
  • Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. 
  • Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains. 
  • Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. 
  • Induction of the ChREBPβ Isoform Is Essential for Glucose-Stimulated β-Cell Proliferation. 
  • Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. 
  • Inflammation does not predispose to bleeding in hemophilia. 
  • Influence of ATM function on telomere metabolism. 
  • Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. 
  • Influence of prothymosin-alpha on HIV-1 target cells. 
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. 
  • Inhibition of G protein-coupled receptor signaling by expression of cytoplasmic domains of the receptor. 
  • Inhibition of HIV-1 proviral DNA synthesis and RNA accumulation by mismatched dsRNA. 
  • Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. 
  • Inhibition of human subconjunctival fibroblast proliferation by immunotoxin. 
  • Inhibition of intimal hyperplasia by direct thrombin inhibitors in an animal vein bypass model. 
  • Inhibition of nitric oxide synthase by cobalamins and cobinamides. 
  • Inhibition of proliferating lens epithelium with antitransferrin receptor immunotoxin. 
  • Inhibition of spontaneous beta 2-adrenergic activation rescues beta 1-adrenergic contractile response in cardiomyocytes overexpressing beta 2-adrenoceptor. 
  • Inhibition of the anaphase-promoting complex by the Xnf7 ubiquitin ligase. 
  • Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody. 
  • Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. 
  • Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase. Functional specificity among G-protein coupled receptor kinases. 
  • Inhibition of translation and induction of apoptosis by Bunyaviral nonstructural proteins bearing sequence similarity to reaper. 
  • Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. 
  • Inhibitor binding increases the mechanical stability of staphylococcal nuclease. 
  • Inhibitor-1, a regulator of protein phosphatase 1 function. 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Initiating a structural study of 2-keto-3-deoxy-6-phosphogluconate aldolase from Escherichia coli. 
  • Injectable tissue integrating networks from recombinant polypeptides with tunable order. 
  • Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. 
  • Inositol 1,4,5-trisphosphate receptor localization and stability in neonatal cardiomyocytes requires interaction with ankyrin-B. 
  • Insulin-like growth factor I induces tumor hexokinase RNA expression in cancer cells. 
  • Insulin-triggered repositioning of munc18c on syntaxin-4 in GLUT4 signalling. 
  • Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. 
  • Integration of cell-free protein coexpression with an enzyme-linked immunosorbent assay enables rapid analysis of protein-protein interactions directly from DNA. 
  • Interaction of NPR1 with basic leucine zipper protein transcription factors that bind sequences required for salicylic acid induction of the PR-1 gene. 
  • Interaction of prenylcysteine methyl esters with the multidrug resistance transporter. 
  • Interaction of the Shiga-like toxin type 1 B-subunit with its carbohydrate receptor. 
  • Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. 
  • Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. 
  • Interactions between beta 2-syntrophin and a family of microtubule-associated serine/threonine kinases. 
  • Interactive discussion on chemotherapy-related adverse events. 
  • Interconversion of red opsin isoforms by the cyclophilin-related chaperone protein Ran-binding protein 2. 
  • Interference of thrombin in immunological assays for hirudin specific antibodies. 
  • Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. 
  • Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. 
  • Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis. 
  • Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). 
  • Interferon-gamma and tumour necrosis factor induce expression of major histocompatibility complex antigen on rat retinal astrocytes. 
  • Interferon-mediated protection of B16 melanoma cells from cytotoxicity by activated macrophages. 
  • Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. 
  • Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. 
  • Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. 
  • Interleukin 10 treatment for rheumatoid arthritis. 
  • Interleukin 2 produced by activated B lymphocytes acts as an autocrine proliferation-inducing lymphokine. 
  • Interleukin-1 beta decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. 
  • Interleukin-1 stimulates diacylglycerol production in T lymphocytes by a novel mechanism. 
  • Interleukin-1 stimulates the beta-amyloid precursor protein promoter. 
  • Interleukin-1-induced nitric oxide production modulates glutathione synthesis in cultured rat hepatocytes. 
  • Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. 
  • Internalization is essential for the antiapoptotic effects of exogenous thymosin beta-4 on human corneal epithelial cells. 
  • International normalized ratio. 
  • Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. 
  • Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. 
  • Intraocular injection of recombinant hirudin to prevent experimental postoperative fibrin. 
  • Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. 
  • Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. 
  • Intrasteric regulation of myosin light chain kinase: the pseudosubstrate prototope binds to the active site. 
  • Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study. 
  • Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. 
  • Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. 
  • Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia. 
  • Investigating the Sensitivity of NAD+-dependent Sirtuin Deacylation Activities to NADH. 
  • Invited commentary. 
  • Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. 
  • Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. 
  • Isolation and characterization of human casein kinase I epsilon (CKI), a novel member of the CKI gene family. 
  • Isolation and heterologous expression of a cDNA encoding bovine inositol polyphosphate 1-phosphatase. 
  • Isolation of protein prenyltransferases from bovine brain and baculovirus expression system. 
  • Keratinocyte growth factor--just another mitogen or the "Holy Grail" that regulates liver regeneration? 
  • Kinetic analysis of zinc ligand mutants of mammalian protein farnesyltransferase. 
  • Kinetic mechanism of adenine phosphoribosyltransferase from Leishmania donovani. 
  • Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. 
  • Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation. 
  • Knock-in tagging in zebrafish facilitated by insertion into non-coding regions. 
  • LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. 
  • Laboratory monitoring of high-dose factor VIIa therapy. 
  • Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators). 
  • Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. 
  • Lefty inhibits receptor-regulated Smad phosphorylation induced by the activated transforming growth factor-beta receptor. 
  • Lefty proteins exhibit unique processing and activate the MAPK pathway. 
  • Leishmania major degrades murine CXCL1 - An immune evasion strategy. 
  • Leptin directly alters lipid partitioning in skeletal muscle. 
  • Leptin regulates proinflammatory immune responses. 
  • Leptin therapy in insulin-deficient type I diabetes. 
  • Lessons From the Studies of a CC Bond Forming Radical SAM Enzyme in Molybdenum Cofactor Biosynthesis. 
  • Leucine periodicity of U2 small nuclear ribonucleoprotein particle (snRNP) A' protein is implicated in snRNP assembly via protein-protein interactions. 
  • Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. 
  • Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast. 
  • Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. 
  • Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. 
  • Long-Segment Fusion for Adult Spinal Deformity Correction Using Low-Dose Recombinant Human Bone Morphogenetic Protein-2: A Retrospective Review of Fusion Rates. 
  • Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy. 
  • Long-term healing of bone using recombinant human bone morphogenetic protein 2. 
  • Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells. 
  • Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. 
  • Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. 
  • Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. 
  • Low-dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation. 
  • Lowering circulating apolipoprotein E levels improves aged bone fracture healing. 
  • Lumenal sites and C terminus accessibility of the skeletal muscle calcium release channel (ryanodine receptor). 
  • Lung EC-SOD overexpression attenuates hypoxic induction of Egr-1 and chronic hypoxic pulmonary vascular remodeling. 
  • Lung development and repair: contribution of the ciliated lineage. 
  • Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. 
  • Lymphokine-activated killer cell activity after cryopreservation. 
  • Lysine(164)alpha of protein farnesyltransferase is important for both CaaX substrate binding and catalysis. 
  • Macromolecular assembly of the transition state regulator AbrB in its unbound and complexed states probed by microelectrospray ionization mass spectrometry. 
  • Making it happen: managed care considerations in vanquishing hepatitis C. 
  • Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. 
  • Maleimide-Functionalized Poly(2-Oxazoline)s and Their Conjugation to Elastin-Like Polypeptides. 
  • Mammalian TRPV4 (VR-OAC) directs behavioral responses to osmotic and mechanical stimuli in Caenorhabditis elegans. 
  • Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. 
  • Management of gynecologic surgery in the patient with factor XI deficiency: a review of the literature. 
  • Management of hepatitis C virus infection: the basics. 
  • Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. 
  • Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. 
  • Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator: a case report and review of treatment options. 
  • Massive transfusion coagulopathy. 
  • Mast cell activation by Mycobacterium tuberculosis: mediator release and role of CD48. 
  • Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. 
  • Mast cell-derived particles deliver peripheral signals to remote lymph nodes. 
  • Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. 
  • Mechanical design of proteins studied by single-molecule force spectroscopy and protein engineering. 
  • Mechanical unfolding intermediates in titin modules. 
  • Mechanism of pokeweed mitogen inhibition of rhIL-4-induced human IgE synthesis. 
  • Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. 
  • Mechanisms and monitoring of bypassing agent therapy. 
  • Mechanisms for regulation of calmodulin kinase IIalpha by Ca(2+)/calmodulin and autophosphorylation of threonine 286. 
  • Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. 
  • Medicine. Stroke--tPA and the clinic. 
  • Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. 
  • Members of the G protein-coupled receptor kinase family that phosphorylate the beta2-adrenergic receptor facilitate sequestration. 
  • Met and hepatocyte growth factor/scatter factor expression in human gliomas. 
  • Metabolic impact of adenovirus-mediated overexpression of the glucose-6-phosphatase catalytic subunit in hepatocytes. 
  • Microarray immunoassay: association of clinical history, in vitro IgE function, and heterogeneity of allergenic peanut epitopes. 
  • Milligram scale production of potent recombinant small interfering RNAs in Escherichia coli. 
  • Mitochondrial phosphatase PTPMT1 is essential for cardiolipin biosynthesis. 
  • Mitogenic and adhesive effects of tenascin-C on human hematopoietic cells are mediated by various functional domains. 
  • Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. 
  • Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. 
  • Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. 
  • Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 
  • Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. 
  • Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency. 
  • Molecular and biochemical characterization of two plant inositol polyphosphate 6-/3-/5-kinases. 
  • Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. 
  • Molecular basis of differential sensitivity of insect sodium channels to DCJW, a bioactive metabolite of the oxadiazine insecticide indoxacarb. 
  • Molecular characterization and functional expression of the DSC1 channel. 
  • Molecular characterization of hypoxia-hypothermia-conditioned human endothelial cells and their interaction with human monocytes. 
  • Molecular cloning and characterization of a novel histone deacetylase HDAC10. 
  • Molecular cloning of aldolases for synthetic applications. 
  • Molecular cloning of dimethyl sulfoxide reductase from Rhodobacter sphaeroides. 
  • Molecular cloning of human liver sulfite oxidase. 
  • Molecular cloning, expression and functional characterization of rabbit anticoagulant vitamin-K-dependent protein S. 
  • Molecular determinants in the second intracellular loop of the 5-hydroxytryptamine-1A receptor for G-protein coupling. 
  • Molecular determinants of nuclear protein phosphatase-1 regulation by NIPP-1. 
  • Molecular mapping of the Cromer blood group Cra and Tca epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology. 
  • Molecular structure and function of the novel BrnT/BrnA toxin-antitoxin system of Brucella abortus. 
  • Molecular structure of the La and Ro autoantigens and their use in autoimmune diagnostics. 
  • Monensin enhances the cytotoxic effect of antitransferrin receptor immunotoxin on cultured RPE cells. 
  • Monitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy. 
  • Monoclonal antibodies to the common gamma-chain as cytokine receptor antagonists in vivo: effect on intrathymic and intestinal intraepithelial T lymphocyte development. 
  • Mononuclear cells from patients with the hyper-IgE syndrome produce little IgE when they are stimulated with recombinant human interleukin-4. 
  • Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. 
  • Most mutations that cause spinocerebellar ataxia autosomal recessive type 16 (SCAR16) destabilize the protein quality-control E3 ligase CHIP. 
  • Mouse germ cell clusters form by aggregation as well as clonal divisions. 
  • Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE). 
  • Multiple proteins interact with the nuclear inhibitory protein repressor element in the human interleukin-3 promoter. 
  • Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. 
  • Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. 
  • Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency (MAIDS) in mice: interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA. 
  • Murine granulocyte-macrophage colony-stimulating factor expressed from a bicistronic simian immunodeficiency virus-based integrase-defective lentiviral vector does not enhance T-cell responses in mice. 
  • Murine monoclonal antibodies specific for conserved and non-conserved antigenic determinants of the human and murine Ku autoantigens. 
  • Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. 
  • Mutational analysis of the fractalkine chemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding, signaling, and cell adhesion. 
  • Myelodysplastic syndromes. 
  • Myeloid growth factors clinical practice guidelines in oncology. 
  • Myeloid growth factors. 
  • N-terminal PDZ domain is required for NHERF dimerization. 
  • NAD+ modulates p53 DNA binding specificity and function. 
  • Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis. 
  • National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. 
  • Native recombinant cyclophilins A, B, and C degrade DNA independently of peptidylprolyl cis-trans-isomerase activity. Potential roles of cyclophilins in apoptosis. 
  • Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. 
  • Neuregulins as potential drugs for neurological disorders. 
  • Neurofilament-L is a protein phosphatase-1-binding protein associated with neuronal plasma membrane and post-synaptic density. 
  • Neurotrophin regulation of ionic currents and cell size depends on cell context. 
  • Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. 
  • Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. 
  • Neutrophil growth factors. 
  • Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. 
  • New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. 
  • New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. 
  • New mass spectrometric assay for angiotensin-converting enzyme 2 activity. 
  • New therapies for chronic hepatitis C virus infection. 
  • Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis. 
  • Newly identified brain potassium channels gated by the guanine nucleotide binding protein Go. 
  • Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes. 
  • Nitric oxide and acetaminophen-mediated oxidative injury: modulation of interleukin-1-induced nitric oxide synthesis in cultured rat hepatocytes. 
  • Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. 
  • Non-erythroid effects of erythropoietin. 
  • Non-redundant roles for interleukin-1 alpha and interleukin-1 beta in regulating human IgG2. 
  • Noncanonical self-assembly of highly asymmetric genetically encoded polypeptide amphiphiles into cylindrical micelles. 
  • Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction. 
  • Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. 
  • Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. 
  • North Carolina stroke prevention and treatment facilities survey: rtPA therapy for acute stroke. 
  • Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. 
  • Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. 
  • Novel oral anticoagulants and reversal agents: Considerations for clinical development. 
  • Novel pharmacologic approaches to reduce bleeding. 
  • NovoSeven for non-hemophilia hemostasis. 
  • Nuclear entry of the circadian regulator mPER1 is controlled by mammalian casein kinase I epsilon. 
  • Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. 
  • Odorant receptors govern the formation of a precise topographic map. 
  • Off-label use of recombinant human factor VIIa. 
  • Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. 
  • Okadaic acid mimics the action of insulin in stimulating protein kinase activity in isolated adipocytes. The role of protein phosphatase 2a in attenuation of the signal. 
  • Oligomeric structure and tissue distribution of ficolins from mouse, pig and human. 
  • Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. 
  • Oncogenic activation of c-ABL by mutation within its last exon. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Optimal Bridging Strategy Post-Ventricular Assist Device Implantation Remains Unclear. 
  • Optimization of expression of human sulfite oxidase and its molybdenum domain. 
  • Ordered phosphorylation of p42mapk by MAP kinase kinase. 
  • Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. 
  • Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. 
  • Outcomes of bone morphogenetic protein-2 in mature adults: posterolateral non-instrument-assisted lumbar decompression and fusion. 
  • Overexpression of the arginine-rich carboxy-terminal region of U1 snRNP 70K inhibits both splicing and nucleocytoplasmic transport of mRNA. 
  • Overproduction and purification of glutaryl 7-amino cephalosporanic acid acylase. 
  • Oxidative stress-induced expression and modulation of Phosphatase of Regenerating Liver-1 (PRL-1) in mammalian retina. 
  • PCI at non-PCI centres: immediate or rescue? 
  • PDGF-BB, IGF-I and mechanical load stimulate DNA synthesis in avian tendon fibroblasts in vitro. 
  • PHAS-I as a link between mitogen-activated protein kinase and translation initiation. 
  • PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. 
  • Palladin is an actin cross-linking protein that uses immunoglobulin-like domains to bind filamentous actin. 
  • Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. 
  • Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group. 
  • Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. 
  • Pattern recognition molecule mindin promotes intranasal clearance of influenza viruses. 
  • Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. 
  • Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. 
  • Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. 
  • Pegfilgrastim: the promise of pegylation fulfilled. 
  • Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. 
  • Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. 
  • Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. 
  • Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. 
  • Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. 
  • Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 
  • Performance of recombinant K39 antigen in the diagnosis of Brazilian visceral leishmaniasis. 
  • Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. 
  • Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. 
  • Persistent, therapeutically relevant levels of human granulocyte colony-stimulating factor in mice after systemic delivery of adeno-associated virus vectors. 
  • Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. 
  • PharmGKB summary: peginterferon-α pathway. 
  • Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques. 
  • Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. 
  • Pharmacokinetics of recombinant transgenic antithrombin in volunteers. 
  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. 
  • Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. 
  • Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. 
  • Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. 
  • Phase I studies of recombinant interferon-gamma. 
  • Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. 
  • Phase I study of recombinant human endostatin in patients with advanced solid tumors. 
  • Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. 
  • Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. 
  • Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. 
  • Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). 
  • Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. 
  • Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. 
  • Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. 
  • Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. 
  • Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. 
  • Phenotypic Correlates of HIV-1 Macrophage Tropism. 
  • Phenotypic and functional consequences of herpesvirus saimiri infection of human CD8+ cytotoxic T lymphocytes. 
  • Phosphatidylcholine transfer protein promotes apolipoprotein A-I-mediated lipid efflux in Chinese hamster ovary cells. 
  • Phosphatidylinositol 3-phosphate and Hsp70 protect Plasmodium falciparum from heat-induced cell death. 
  • Phosphatidylinositol 4,5-bisphosphate (PIP2)-enhanced G protein-coupled receptor kinase (GRK) activity. Location, structure, and regulation of the PIP2 binding site distinguishes the GRK subfamilies. 
  • Phosphorus-based SAHA analogues as histone deacetylase inhibitors. 
  • Phosphorylation and nuclear translocation of a regulator of G protein signaling (RGS10). 
  • Phosphorylation of DHBV pre-S: identification of the major site of phosphorylation and effects of mutations on the virus life cycle. 
  • Phosphorylation of Gz alpha by protein kinase C blocks interaction with the beta gamma complex. 
  • Phosphorylation of Gz in human platelets. Selectivity and site of modification. 
  • Phosphorylation of PHAS-I by mitogen-activated protein (MAP) kinase. Identification of a site phosphorylated by MAP kinase in vitro and in response to insulin in rat adipocytes. 
  • Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. 
  • Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK. 
  • Phosphorylation of phosphatase inhibitor-2 at centrosomes during mitosis. 
  • Phosphorylation of telokin by cyclic nucleotide kinases and the identification of in vivo phosphorylation sites in smooth muscle. 
  • Phosphorylation sites on two domains of the beta 2-adrenergic receptor are involved in distinct pathways of receptor desensitization. 
  • Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. 
  • Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. 
  • Plasmid models for bacteriophage T4 DNA replication: requirements for fork proteins. 
  • Platelet binding and activity of recombinant factor VIIa. 
  • Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. 
  • Platelet function and fibrinolytic agents: two sides of a coin? 
  • Pollutant particles induce arginase II in human bronchial epithelial cells. 
  • Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. 
  • Polyribonucleotides induce nitric oxide production by human monocyte-derived macrophages. 
  • Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. 
  • Porcine CD80: cloning, characterization, and evidence for its role in direct human T-cell activation. 
  • Positively selected Leu-11a (CD16+) cells require the presence of accessory cells or factors for the lysis of herpes simplex virus-infected fibroblasts but not herpes simplex virus-infected Raji. 
  • Postpartum hemorrhage: when uterotonics and sutures fail. 
  • Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. 
  • Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. 
  • Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy. 
  • Predictors of consent to pharmacogenomics testing in the IDEAL study. 
  • Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. 
  • Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. 
  • Pregnancy lactogens in the rat conceptus and fetus: circulating levels, distribution of binding, and expression of receptor messenger ribonucleic acid. 
  • Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species. 
  • Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. 
  • Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. 
  • Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. 
  • Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. 
  • Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. 
  • Probing RNA Structure in Liquid-Liquid Phase Separation Using SHAPE-MaP. 
  • Processive post-translational modification. Vitamin K-dependent carboxylation of a peptide substrate. 
  • Production of a retroviral P15E-related chemotaxis inhibitor by IL-1-treated endothelial cells. A possible negative feedback in the regulation of the vascular response to monokines. 
  • Progesterone Metabolites Produced by Cytochrome P450 3A Modulate Uterine Contractility in a Murine Model. 
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. 
  • Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. 
  • Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). 
  • Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. 
  • Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. 
  • Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. 
  • Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type I. 
  • Properties of the beta 1- and beta 2-adrenergic receptor subtypes revealed by molecular cloning. 
  • Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature. 
  • Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. 
  • Prostaglandin E2-mediated regulation of immunoglobulin G2 via interferon gamma. 
  • Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. 
  • Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. 
  • Protection against platelet-activating factor-induced injury by interferon inducer in perfused rabbit lung. 
  • Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. 
  • Protein kinase A-mediated phosphorylation of the beta 2-adrenergic receptor regulates its coupling to Gs and Gi. Demonstration in a reconstituted system. 
  • Protein kinase C beta II specifically binds to and is activated by F-actin. 
  • Protein kinase CK2 phosphorylates the cell cycle regulatory protein Geminin. 
  • Protein phosphorylation is a regulatory mechanism for O6-alkylguanine-DNA alkyltransferase in human brain tumor cells. 
  • Protein synthesis-dependent potentiation by thyroxine of antiviral activity of interferon-gamma. 
  • Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. 
  • Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. 
  • Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. 
  • Protocolized hemostatic factor use in major thoracic aortic surgery. 
  • Pulmonary artery thrombus in a premature neonate treated with recombinant tissue plasminogen activator. 
  • Pulmonary embolism after administration of recombinant activated Factor VII for major obstetric hemorrhage. 
  • Pulsed EPR studies of nonexchangeable protons near the Mo(V) center of sulfite oxidase: direct detection of the alpha-proton of the coordinated cysteinyl residue and structural implications for the active site. 
  • Pulsed EPR studies of the exchangeable proton at the molybdenum center of dimethyl sulfoxide reductase. 
  • Pure red cell aplasia following pegylated interferon alpha treatment. 
  • Purification and characterization of recombinant human mineralocorticoid receptor. 
  • Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis. 
  • Purification and partial characterization of a human hematopoietic precursor population. 
  • Purification of recombinant proteins by fusion with thermally-responsive polypeptides. 
  • Purification of recombinant proteins from Escherichia coli at low expression levels by inverse transition cycling 
  • Purification, cloning, and expression of a peripheral-type benzodiazepine receptor. 
  • Purification, crystallization and preliminary X-ray diffraction studies of a complex between G protein-coupled receptor kinase 2 and Gbeta1gamma2. 
  • Purified lymphocyte function-associated antigen-3 (LFA-3) activates human thymocytes via the CD2 pathway. 
  • Putative human blue-light photoreceptors hCRY1 and hCRY2 are flavoproteins. 
  • Pyruvate aldolases in chiral carbon-carbon bond formation. 
  • Quantitative Proteomics Links the LRRC59 Interactome to mRNA Translation on the ER Membrane. 
  • Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity. 
  • Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. 
  • Quantitative and selective fluorophore labeling of phosphoserine on peptides and proteins: characterization at the attomole level by capillary electrophoresis and laser-induced fluorescence. 
  • RCC1, a regulator of mitosis, is essential for DNA replication. 
  • RELAX-AHF: consistency across subgroups and new hypotheses generated. 
  • RGSZ1, a Gz-selective regulator of G protein signaling whose action is sensitive to the phosphorylation state of Gzalpha. 
  • RNA-binding domain of the A protein component of the U1 small nuclear ribonucleoprotein analyzed by NMR spectroscopy is structurally similar to ribosomal proteins. 
  • Rabbit plasma, unlike its human counterpart, contains no complex between protein S and C4b-binding protein. 
  • Racial differences in hepatitis C treatment eligibility. 
  • Radical Breakthroughs in Natural Product and Cofactor Biosynthesis. 
  • Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. 
  • Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. 
  • Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. 
  • Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. 
  • Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. 
  • Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. 
  • Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. 
  • Rapid generation of potent antibodies by autonomous hypermutation in yeast. 
  • Rapid identification of protein phosphatase 1-binding proteins by mixed peptide sequencing and data base searching. Characterization of a novel holoenzymic form of protein phosphatase 1. 
  • Rapid kinetic-based screening of human Fab fragments. 
  • Rat liver NAD(P)H:quinone oxidoreductase: cDNA expression and site-directed mutagenesis. 
  • Rate of vascularization of coralline hydroxyapatite spherical implants pretreated with saline/gentamicin, rTGF-beta 2, and autogenous plasma. 
  • Re-design of Rhodobacter sphaeroides dimethyl sulfoxide reductase. Enhancement of adenosine N1-oxide reductase activity. 
  • Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. 
  • Reaction mechanism of (6-4) photolyase. 
  • Reaction path of protein farnesyltransferase at atomic resolution. 
  • Reaction phenotyping of vinblastine metabolism in dogs. 
  • Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. 
  • Reaper is regulated by IAP-mediated ubiquitination. 
  • Reaper-induced dissociation of a Scythe-sequestered cytochrome c-releasing activity. 
  • Recent developments in topical thrombins. 
  • Receptor and G betagamma isoform-specific interactions with G protein-coupled receptor kinases. 
  • Receptor-tyrosine-kinase- and G beta gamma-mediated MAP kinase activation by a common signalling pathway. 
  • Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. 
  • Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. 
  • Recombinant HMGB1 with cytokine-stimulating activity. 
  • Recombinant Human Antithrombin in Pregnant Patients with Hereditary Antithrombin Deficiency: Integrated Analysis of Clinical Data. 
  • Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques. 
  • Recombinant Rhodobacter capsulatus xanthine dehydrogenase, a useful model system for the characterization of protein variants leading to xanthinuria I in humans. 
  • Recombinant Thrombomodulin Attenuates Preeclamptic Symptoms by Inhibiting High-Mobility Group Box 1 in Mice. 
  • Recombinant activated factor VII and the anaesthetist. 
  • Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. 
  • Recombinant activated factor VIIa treatment for refractory hemorrhage in infants. 
  • Recombinant acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) purified to essential homogeneity utilizes cholesterol in mixed micelles or in vesicles in a highly cooperative manner. 
  • Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. 
  • Recombinant antithrombin: production and role in cardiovascular disorder. 
  • Recombinant biologics for treatment of bleeding disorders. 
  • Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. 
  • Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. 
  • Recombinant hirudin displaces human factor Xa from its endothelial binding sites. 
  • Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. 
  • Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery. 
  • Recombinant human IL-4 induces IgE and IgG synthesis by normal and atopic donor mononuclear cells. Similar dose response, time course, requirement for T cells, and effect of pokeweed mitogen. 
  • Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts. 
  • Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. 
  • Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. 
  • Recombinant human bone morphogenetic protein-2 as an adjunct for spine fusion in a pediatric population. 
  • Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells. 
  • Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence. 
  • Recombinant human glial growth factor 2 (rhGGF2) improves functional recovery of crushed peripheral nerve (a double-blind study). 
  • Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. 
  • Recombinant human interleukin 1 alpha: purification and biological characterization. 
  • Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. 
  • Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. 
  • Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. 
  • Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts. 
  • Recombinant human uteroglobin inhibits the in vitro invasiveness of human metastatic prostate tumor cells and the release of arachidonic acid stimulated by fibroblast-conditioned medium. 
  • Recombinant hydrophilic region of murine retroviral protein p15E inhibits stimulated T-lymphocyte proliferation. 
  • Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation. 
  • Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. 
  • Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. 
  • Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India. 
  • Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. 
  • Recombinant polyclonal antibody libraries. 
  • Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion. 
  • Reconstitution of contractile FtsZ rings in liposomes. 
  • Reconstitution of mitochondrial processing peptidase from the core proteins (subunits I and II) of bovine heart mitochondrial cytochrome bc(1) complex. 
  • Reconstitution of nuclear protein export in isolated nuclear envelopes. 
  • Reconstitution of the vitamin D-responsive osteocalcin transcription unit in Saccharomyces cerevisiae. 
  • Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules. 
  • Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. 
  • Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. 
  • Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. 
  • Regeneration of fat cells from myofibroblasts during wound healing. 
  • Regression of atherosclerosis with therapeutic antibodies pipe cleaner or pipe dream? 
  • Regulation and function of the calcium/calmodulin-dependent protein kinase IV/protein serine/threonine phosphatase 2A signaling complex. 
  • Regulation of ALK-1 signaling by the nuclear receptor LXRbeta. 
  • Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha. 
  • Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. 
  • Regulation of a cyclin-CDK-CDK inhibitor complex by inositol pyrophosphates. 
  • Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. 
  • Regulation of biliary secretion through apical purinergic receptors in cultured rat cholangiocytes. 
  • Regulation of deactivation of photoreceptor G protein by its target enzyme and cGMP. 
  • Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes. 
  • Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction. 
  • Regulation of membrane release in apoptosis. 
  • Regulation of mitogen-activated protein kinase pathways by catecholamine receptors. 
  • Regulation of overexpressed hexokinases in liver and islet cells. 
  • Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. 
  • Regulation of the extracellular antioxidant selenoprotein plasma glutathione peroxidase (GPx-3) in mammalian cells. 
  • Regulation of the platelet-derived growth factor receptor-beta by G protein-coupled receptor kinase-5 in vascular smooth muscle cells involves the phosphatase Shp2. 
  • Regulation of the uncoupling protein-2 gene in INS-1 beta-cells by oleic acid. 
  • Regulation of zipper-interacting protein kinase activity in vitro and in vivo by multisite phosphorylation. 
  • Regulatory elements governing transcription in specialized myofiber subtypes. 
  • Reinterpretation of GCN4-p1 folding kinetics: partial helix formation precedes dimerization in coiled coil folding. 
  • Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. 
  • Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. 
  • Release of ubiquitin-charged Cdc34-S - Ub from the RING domain is essential for ubiquitination of the SCF(Cdc4)-bound substrate Sic1. 
  • Renal allograft-infiltrating lymphocytes. A prospective analysis of in vitro growth characteristics and clinical relevance. 
  • Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. 
  • Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report. 
  • Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. 
  • Representativeness of RELAX-AHF clinical trial population in acute heart failure. 
  • Repression of mesodermal fate by foxa, a key endoderm regulator of the sea urchin embryo. 
  • Requirement of the Src homology 2 domain protein Shb for T cell receptor-dependent activation of the interleukin-2 gene nuclear factor for activation of T cells element in Jurkat T cells. 
  • Requirement of the prolyl isomerase Pin1 for the replication checkpoint. 
  • Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. 
  • Resistance to adenovirally induced hyperleptinemia in rats. Comparison of ventromedial hypothalamic lesions and mutated leptin receptors. 
  • Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. 
  • Reteplase but not alteplase affects early soluble PECAM-1 and P-selectin release in patients with acute myocardial infarction. 
  • Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. 
  • Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. 
  • Reversal agents for non-vitamin K antagonist oral anticoagulants. 
  • Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper. 
  • Reversing adipocyte differentiation: implications for treatment of obesity. 
  • Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions. 
  • Rh-related antigen CD47 is the signal-transducer integrin-associated protein. 
  • Right ventricular gene therapy with a beta-adrenergic receptor kinase inhibitor improves survival after pulmonary artery banding. 
  • Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia. 
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. 
  • Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. 
  • Robust and facile purification of full-length, untagged human Nedd4 as a recombinant protein from Escherichia coli. 
  • Role for hedgehog signaling in hepatic stellate cell activation and viability. 
  • Role of C-terminal serines in desensitization and phosphorylation of the mouse thromboxane receptor. 
  • Role of Pseudomonas aeruginosa dinB-encoded DNA polymerase IV in mutagenesis. 
  • Role of arginine 180 and glutamic acid 177 of ricin toxin A chain in enzymatic inactivation of ribosomes. 
  • Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. 
  • Role of beta-arrestins in the intracellular trafficking of G-protein-coupled receptors. 
  • Role of conserved tyrosine 343 in intramolecular electron transfer in human sulfite oxidase. 
  • Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. 
  • Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. 
  • Role of phosphate-magnesium-binding regions in the high GTPase activity of rac1 protein. 
  • Role of phospholipase Cbeta3 phosphorylation in the desensitization of cellular responses to platelet-activating factor. 
  • Roles of v-erbA homodimers and heterodimers in mediating dominant negative activity by v-erbA. 
  • Rotation of the stalk/neck and one head in a new crystal structure of the kinesin motor protein, Ncd. 
  • Routine bivalirudin use in percutaneous carotid interventions. 
  • S100A8 protein attenuates airway hyperresponsiveness by suppressing the contraction of airway smooth muscle. 
  • SAC1-like domains of yeast SAC1, INP52, and INP53 and of human synaptojanin encode polyphosphoinositide phosphatases. 
  • SCF E3-mediated autoubiquitination negatively regulates activity of Cdc34 E2 but plays a nonessential role in the catalytic cycle in vitro and in vivo. 
  • SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. 
  • SLLP1, a unique, intra-acrosomal, non-bacteriolytic, c lysozyme-like protein of human spermatozoa. 
  • SMRTER, a Drosophila nuclear receptor coregulator, reveals that EcR-mediated repression is critical for development. 
  • Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. 
  • Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. 
  • Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. 
  • Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. 
  • Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. 
  • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. 
  • Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents. 
  • Safety profile of recombinant factor VIIa. 
  • Safety, efficacy, and dosing of recombinant human bone morphogenetic protein-2 for posterior cervical and cervicothoracic instrumented fusion with a minimum 2-year follow-up. 
  • Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. 
  • Sarcoidosis induced by interferon therapy. 
  • Saturation mutagenesis of His114 of EcoRI reveals relaxed-specificity mutants. 
  • Scaffold-based rhBMP-2 therapy in a rat alveolar defect model: implications for human gingivoperiosteoplasty. 
  • Scar/WAVE-1, a Wiskott-Aldrich syndrome protein, assembles an actin-associated multi-kinase scaffold. 
  • Schedule-dependent enhanced lethality with combined administration of actinomycin D and tumor necrosis factor in mice. 
  • Scythe: a novel reaper-binding apoptotic regulator. 
  • Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. 
  • Secreted extracellular domains of macrophage scavenger receptors form elongated trimers which specifically bind crocidolite asbestos. 
  • Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. 
  • Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display. 
  • Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. 
  • Selective mutations in cloned and expressed alpha-macroglobulin receptor binding fragment alter binding to either the alpha2-macroglobulin signaling receptor or the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor. 
  • Septin ring assembly involves cycles of GTP loading and hydrolysis by Cdc42p. 
  • Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. 
  • Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. 
  • Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 
  • Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. 
  • Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. 
  • Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. 
  • Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. 
  • Serotonin 5-HT1A receptor-mediated Erk activation requires calcium/calmodulin-dependent receptor endocytosis. 
  • Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. 
  • Seven-up inhibits ultraspiracle-based signaling pathways in vitro and in vivo. 
  • Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. 
  • Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. 
  • Short-term integration of Cdc25 dynamics controls mitotic entry during Drosophila gastrulation. 
  • Short-term regulation of Na+/K+ adenosine triphosphatase by recombinant human serotonin 5-HT1A receptor expressed in HeLa cells. 
  • Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site. 
  • Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. 
  • Site-directed mutagenesis of recombinant sulfite oxidase: identification of cysteine 207 as a ligand of molybdenum. 
  • Site-directed mutagenesis studies of the high-affinity streptavidin-biotin complex: contributions of tryptophan residues 79, 108, and 120. 
  • Site-specific mutagenesis of Drosophila alcohol dehydrogenase: evidence for involvement of tyrosine-152 and lysine-156 in catalysis. 
  • Sites of interaction between kinase-related protein and smooth muscle myosin. 
  • Skewed VH and V kappa gene family expression and pairing occurs among B lymphocytes in autoimmune motheaten mice. 
  • Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. 
  • Small near-infrared photochromic protein for photoacoustic multi-contrast imaging and detection of protein interactions in vivo. 
  • Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein kinase. 
  • Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides. 
  • Sodium binding site of factor Xa: role of sodium in the prothrombinase complex. 
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. 
  • Soluble miniagrin enhances contractile function of engineered skeletal muscle. 
  • Soluble recombinant neutral endopeptidase (CD10) as a potential antiinflammatory agent. 
  • Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents. 
  • Special issue on engineered DNA-binding proteins. 
  • Specific 33-residue repeat(s) of erythrocyte ankyrin associate with the anion exchanger. 
  • Specific binding of RGS9-Gbeta 5L to protein anchor in photoreceptor membranes greatly enhances its catalytic activity. 
  • Specific interactions of Mss4 with members of the Rab GTPase subfamily. 
  • Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte. 
  • Specificity determinants in phosphoinositide dephosphorylation: crystal structure of an archetypal inositol polyphosphate 5-phosphatase. 
  • Specificity of autoantibodies for recombinant 60-kd and 52-kd Ro autoantigens. 
  • Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. 
  • Stability of recombinant tissue plasminogen activator. 
  • Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. 
  • Stable expression of manganese superoxide dismutase (MnSOD) in insulinoma cells prevents IL-1beta- induced cytotoxicity and reduces nitric oxide production. 
  • State of the art: von Willebrand disease. 
  • Staurosporine inhibition of zipper-interacting protein kinase contractile effects in gastrointestinal smooth muscle. 
  • Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. 
  • Stereochemical aspects of itraconazole metabolism in vitro and in vivo. 
  • Stereochemical recognition of doubly functional aminotransferase in 2-deoxystreptamine biosynthesis. 
  • Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants. 
  • Stimulation of Sky tyrosine phosphorylation by bovine protein S--domains involved in the receptor-ligand interaction. 
  • Stimulation of brain hexokinase gene expression by recombinant brain insulin-like growth factor in C6 glial cells. 
  • Stimulation of human and rat islet beta-cell proliferation with retention of function by the homeodomain transcription factor Nkx6.1. 
  • Streptokinase versus alteplase in acute myocardial infarction. 
  • Structural analyses of Ca²⁺/CaM interaction with NaV channel C-termini reveal mechanisms of calcium-dependent regulation. 
  • Structural and functional characterization of monomeric soluble P-selectin and comparison with membrane P-selectin. 
  • Structural and functional domains of the Drosophila ncd microtubule motor protein. 
  • Structural basis for the metal-selective activation of the manganese transport regulator of Bacillus subtilis. 
  • Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters. 
  • Structural characterization of the 5' regions of the human phenylalanine hydroxylase gene. 
  • Structural conservation of ion conduction pathways in K channels and glutamate receptors. 
  • Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator. 
  • Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. 
  • Structural organization of the human insulin receptor ectodomain. 
  • Structural studies of phosphorylation-dependent interactions between the V2R receptor and arrestin-2. 
  • Structure and function of the native and recombinant mitochondrial MRP1/MRP2 complex from Trypanosoma brucei. 
  • Structure and hydride transfer mechanism of a moderate thermophilic dihydrofolate reductase from Bacillus stearothermophilus and comparison to its mesophilic and hyperthermophilic homologues. 
  • Structure and stability of monomeric lambda repressor: NMR evidence for two-state folding. 
  • Structure of FitAB from Neisseria gonorrhoeae bound to DNA reveals a tetramer of toxin-antitoxin heterodimers containing pin domains and ribbon-helix-helix motifs. 
  • Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein. 
  • Structure of the LpxC deacetylase with a bound substrate-analog inhibitor. 
  • Structure of the Trypanosoma brucei p22 protein, a cytochrome oxidase subunit II-specific RNA-editing accessory factor. 
  • Structure of the manganese-bound manganese transport regulator of Bacillus subtilis. 
  • Structure of the molybdenum site of Rhodobacter sphaeroides biotin sulfoxide reductase. 
  • Structure, binding interface and hydrophobic transitions of Ca2+-loaded calbindin-D(28K). 
  • Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield. 
  • Structure-function of recombinant Na/H exchanger regulatory factor (NHE-RF). 
  • Structures of the activator of K. pneumonia biofilm formation, MrkH, indicates PilZ domains involved in c-di-GMP and DNA binding. 
  • Structures of yeast vesicle trafficking proteins. 
  • Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. 
  • Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. 
  • Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. 
  • Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. 
  • Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. 
  • Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). 
  • Substitution of cadmium for zinc in farnesyl:protein transferase alters its substrate specificity. 
  • Substrate recognition by the EcoRI endonuclease. 
  • Subtype-specific binding of azidoanilido-GTP by purified G protein alpha subunits. 
  • Subunit IV of cytochrome bc1 complex from Rhodobacter sphaeroides. Localization of regions essential for interaction with the three-subunit core complex. 
  • Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. 
  • Suppression of human corneal epithelial proliferation with breast carcinoma immunotoxin. 
  • Surfactant protein A is defective in abrogating inflammation in asthma. 
  • Surfactant protein D decreases pollen-induced IgE-dependent mast cell degranulation. 
  • Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. 
  • Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. 
  • Sustained release of BMP-2 in a lipid-based microtube vehicle. 
  • Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. 
  • Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. 
  • Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. 
  • Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease. 
  • Synergistic effect of dexamethasone and isoproterenol on the expression of angiotensinogen in immortalized rat proximal tubular cells. 
  • Synthesis and in vitro evaluation of enzymatically cross-linked elastin-like polypeptide gels for cartilaginous tissue repair. 
  • Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach. 
  • Systemic antiviral drugs used in ophthalmology. 
  • Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency. 
  • Systemic hemostasis with recombinant-activated factor VII followed by local thrombolysis with recombinant tissue plasminogen activator in intraventricular hemorrhage. 
  • Systemic production of human granulocyte colony-stimulating factor in nonhuman primates by transplantation of genetically modified myoblasts. 
  • T-antigen kinase inhibits simian virus 40 DNA replication by phosphorylation of intact T antigen on serines 120 and 123. 
  • T-cell-receptor affinity and thymocyte positive selection. 
  • TBX5-encoded T-box transcription factor 5 variant T223M is associated with long QT syndrome and pediatric sudden cardiac death. 
  • TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. 
  • Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. 
  • Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. 
  • Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. 
  • Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. 
  • Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. 
  • Tau induces formation of α-synuclein filaments with distinct molecular conformations. 
  • Telaprevir for previously treated chronic HCV infection. 
  • Telaprevir for previously untreated chronic hepatitis C virus infection. 
  • Telaprevir for the treatment of chronic hepatitis C infection. 
  • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. 
  • Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. 
  • Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells. Localization of active regions using recombinant tenascin fragments. 
  • Tepoxalin enhances the activity of an antioxidant, pyrrolidine dithiocarbamate, in attenuating tumor necrosis factor alpha-induced apoptosis in WEHI 164 cells. 
  • The 100-kDa proteolytic fragment of RB is retained predominantly within the nuclear compartment of apoptotic cells. 
  • The 2.0 A crystal structure of a heterotrimeric G protein. 
  • The Affinity of Brominated Phenolic Compounds for Human and Zebrafish Thyroid Receptor β: Influence of Chemical Structure. 
  • The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target. 
  • The CD19 signal transduction complex of B lymphocytes. Deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13. 
  • The COPI complex functions in nuclear envelope breakdown and is recruited by the nucleoporin Nup153. 
  • The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. 
  • The DEXH protein product of the DHX36 gene is the major source of tetramolecular quadruplex G4-DNA resolving activity in HeLa cell lysates. 
  • The Drosophila claret segregation protein is a minus-end directed motor molecule. 
  • The Expression of Functional Vpx during Pathogenic SIVmac Infections of Rhesus Macaques Suppresses SAMHD1 in CD4+ Memory T Cells. 
  • The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid. 
  • The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. 
  • The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry CathPCI Registry. 
  • The Judicious Use of Recombinant Factor VIIa. 
  • The N2-ethylguanine and the O6-ethyl- and O6-methylguanine lesions in DNA: contrasting responses from the "bypass" DNA polymerase eta and the replicative DNA polymerase alpha. 
  • The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids. 
  • The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. 
  • The T4 phage SF1B helicase Dda is structurally optimized to perform DNA strand separation. 
  • The Trim39 ubiquitin ligase inhibits APC/CCdh1-mediated degradation of the Bax activator MOAP-1. 
  • The U1 small nuclear ribonucleoprotein (snRNP) 70K protein is transported independently of U1 snRNP particles via a nuclear localization signal in the RNA-binding domain. 
  • The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. 
  • The active conformation of beta-arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins1 and -2. 
  • The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. 
  • The antiproliferative effect of a transferrin-toxin on human retinal pigment epithelial cells and rabbit fibroblasts. 
  • The autonomous activity of calcium/calmodulin-dependent protein kinase IV is required for its role in transcription. 
  • The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA. 
  • The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. 
  • The compact conformation of fibronectin is determined by intramolecular ionic interactions. 
  • The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics. 
  • The cyclic AMP response element directs tyrosine hydroxylase expression in catecholaminergic central and peripheral nervous system cell lines from transgenic mice. 
  • The distinct binding specificities exhibited by enterobacterial type 1 fimbriae are determined by their fimbrial shafts. 
  • The disulfide bonding pattern in ficolin multimers. 
  • The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro. 
  • The economic burden of anemia in cancer patients receiving chemotherapy. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation. 
  • The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. 
  • The effect of variance function estimation on nonlinear calibration inference in immunoassay data. 
  • The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center. 
  • The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. 
  • The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. 
  • The expression of a functional, secreted human lysyl hydroxylase in a baculovirus system. 
  • The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. 
  • The human cytokine I-309 is a monocyte chemoattractant. 
  • The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. 
  • The impact of anaemia and its treatment on employee disability and medical costs. 
  • The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. 
  • The importance of Src homology 2 domain-containing leukocyte phosphoprotein of 76 kilodaltons sterile-alpha motif domain in thymic selection and T-cell activation. 
  • The indolocarbazole Gö6976 protects neurons from lipopolysaccharide/interferon-gamma-induced cytotoxicity in murine neuron/glia co-cultures. 
  • The inhibitor-1 C terminus facilitates hormonal regulation of cellular protein phosphatase-1: functional implications for inhibitor-1 isoforms. 
  • The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. 
  • The matrix protein Fibulin-5 is at the interface of tissue stiffness and inflammation in fibrosis. 
  • The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. 
  • The membrane-binding domain of ankyrin contains four independently folded subdomains, each comprised of six ankyrin repeats. 
  • The molecular basis of class II MHC allelic control of T cell responses. 
  • The molecular elasticity of the extracellular matrix protein tenascin. 
  • The motion of a single molecule, the lambda-receptor, in the bacterial outer membrane. 
  • The neuronal actin-binding proteins, neurabin I and neurabin II, recruit specific isoforms of protein phosphatase-1 catalytic subunits. 
  • The non-haematopoietic biological effects of erythropoietin. 
  • The nucleolar localization domain of the catalytic subunit of human telomerase. 
  • The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. 
  • The pathway mediating insulin's effects on pyruvate dehydrogenase bypasses the insulin receptor tyrosine kinase. 
  • The physiology of jaundice: molecular and functional characterization of the Crigler-Najjar syndromes. 
  • The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. 
  • The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. 
  • The production and characterization of murine monoclonal antibodies to human Gadd45 raised against a recombinant protein. 
  • The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. 
  • The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. 
  • The regulation of the cGMP-binding cGMP phosphodiesterase by proteins that are immunologically related to gamma subunit of the photoreceptor cGMP phosphodiesterase. 
  • The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? 
  • The relationship between ligand-binding thermodynamics and protein-ligand interaction forces measured by atomic force microscopy. 
  • The rho-guanine nucleotide exchange factor domain of obscurin regulates assembly of titin at the Z-disk through interactions with Ran binding protein 9. 
  • The role for interleukin-12 therapy of cutaneous T cell lymphoma. 
  • The role of CD4-Lck in T-cell receptor antagonism: evidence for negative signaling. 
  • The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue? 
  • The role of carbohydrate in the function of human plasminogen: comparison of the protein obtained from molecular cloning and expression in Escherichia coli and COS cells. 
  • The role of functionally distinct helper T lymphocyte subpopulations in the induction of human B cell differentiation. 
  • The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy. 
  • The role of the specificity-determining loop of the integrin beta subunit I-like domain in autonomous expression, association with the alpha subunit, and ligand binding. 
  • The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012. 
  • The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. 
  • The structural basis for the selectivity of benzotriazole inhibitors of PTP1B. 
  • The structure of irisin reveals a novel intersubunit β-sheet fibronectin type III (FNIII) dimer: implications for receptor activation. 
  • The substance P receptor, which couples to Gq/11, is a substrate of beta-adrenergic receptor kinase 1 and 2. 
  • The suppressive effect of a synthetic retroviral peptide on the human IFN gamma production is abrogated by the combined stimulation with IL-1 and IL-2. 
  • The three-dimensional structure of H-2Db at 2.4 A resolution: implications for antigen-determinant selection. 
  • The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. 
  • The type I and type II bovine scavenger receptors expressed in Chinese hamster ovary cells are trimeric proteins with collagenous triple helical domains comprising noncovalently associated monomers and Cys83-disulfide-linked dimers. 
  • The use of allograft and recombinant human bone morphogenetic protein for instrumented atlantoaxial fusions. 
  • The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. 
  • The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: case series and review of the literature. 
  • The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. 
  • The uterine myometrium is a target for increased levels of activin A during pregnancy. 
  • The winged-helix/forkhead protein myocyte nuclear factor beta (MNF-beta) forms a co-repressor complex with mammalian sin3B. 
  • Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. 
  • Therapy of acute and fulminant hepatitis B. 
  • Thermodynamic characterization of the binding interaction between the histone demethylase LSD1/KDM1 and CoREST. 
  • Thermodynamics of oxidation-reduction reactions in mammalian nitric-oxide synthase isoforms. 
  • Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice. 
  • Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. 
  • Three amino acid substitutions in domain I of calmodulin prevent the activation of chicken smooth muscle myosin light chain kinase. 
  • Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. 
  • Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. 
  • Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. 
  • Thrombin primes responsiveness of selective chemoattractant receptors at a site distal to G protein activation. 
  • Thrombin-catalyzed activation of recombinant human factor V. 
  • Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. 
  • Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. 
  • Thromboxane A2modulates the fibrinolytic system in glomerular mesangial cells. 
  • Time-dependent inhibition of isoprenylcysteine carboxyl methyltransferase by indole-based small molecules. 
  • Tissue interactions pattern the mesenchyme of the embryonic mouse lung. 
  • Tissue plasminogen activator concentration dependence of 120 kHz ultrasound-enhanced thrombolysis. 
  • Tissue plasminogen activator for postvitrectomy fibrin formation. 
  • Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. 
  • Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. 
  • Tissue transglutaminase is expressed as a host response to tumor invasion and inhibits tumor growth. 
  • Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. 
  • Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial. 
  • Total chemical synthesis and biophysical characterization of the minimal isoform of the KChIP2 potassium channel regulatory subunit. 
  • Tracking the in vivo fate of recombinant polypeptides by isotopic labeling. 
  • Trans-activating rev protein of the human immunodeficiency virus 1 interacts directly and specifically with its target RNA. 
  • Transcription factor AP-2 regulates human immunodeficiency virus type 1 gene expression. 
  • Transcription interruption may be a common mechanism of c-myc regulation during HL-60 differentiation. 
  • Transcriptional regulation of the cholesteryl ester transfer protein gene by the orphan nuclear hormone receptor apolipoprotein AI regulatory protein-1. 
  • Transcriptional regulatory functions of heterogeneous nuclear ribonucleoprotein-U and -A/B in endotoxin-mediated macrophage expression of osteopontin. 
  • Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. 
  • Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. 
  • Transgene expression in zebrafish: A comparison of retroviral-vector and DNA-injection approaches. 
  • Transgenic manipulation of the metabolism of polyamines in poplar cells. 
  • Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. 
  • Treatment of acute hepatitis C infection: more pieces of the puzzle? 
  • Treatment of acute hepatitis C with interferon alfa-2b. 
  • Treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). 
  • Treatment of hepatitis C in special populations. 
  • Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. 
  • Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. 
  • Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 
  • Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). 
  • Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. 
  • Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. 
  • Triiodothyronine (T3) differentially affects T3-receptor/retinoic acid receptor and T3-receptor/retinoid X receptor heterodimer binding to DNA. 
  • TrkB-Shc Signaling Protects against Hippocampal Injury Following Status Epilepticus. 
  • Truncated forms of the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor encompassing the IGF-II binding site: characterization of a point mutation that abolishes IGF-II binding. 
  • Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. 
  • Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. 
  • Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. 
  • Tumor necrosis factor promotes motor functional recovery in crushed peripheral nerve. 
  • Tumor necrosis factor-alpha induces c-jun during the regenerative response to liver injury. 
  • Tumor necrosis factor-alpha-induced lung injury and its modulation by synthetic polynucleotide: a physiologic-morphometric analysis. 
  • Two proteins of the Dictyostelium spore coat bind to cellulose in vitro. 
  • Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. 
  • Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. 
  • Ultramicrosurgical removal of subretinal hemorrhage in cats. 
  • Ultrastructure and function of dimeric, soluble intercellular adhesion molecule-1 (ICAM-1). 
  • Understanding the elasticity of fibronectin fibrils: unfolding strengths of FN-III and GFP domains measured by single molecule force spectroscopy. 
  • Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc. 
  • Update on neutropenia and myeloid growth factors. 
  • Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. 
  • Uricase and other novel agents for the management of patients with treatment-failure gout. 
  • Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. 
  • Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. 
  • Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. 
  • Use of a vascular reconstruction device to salvage acute ischemic occlusions refractory to traditional endovascular recanalization methods. 
  • Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). 
  • Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. 
  • Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. 
  • Use of rhBMP-2 for adult spinal deformity surgery: patterns of usage and changes over the past decade. 
  • Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. 
  • Uses of epoetin for anemia in oncology. 
  • VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. 
  • VEGF increases retinal vascular ICAM-1 expression in vivo. 
  • Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. 
  • Vaccine-Mediated Inhibition of the Transporter Associated with Antigen Processing Is Insufficient To Induce Major Histocompatibility Complex E-Restricted CD8+ T Cells in Nonhuman Primates. 
  • Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. 
  • Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus. 
  • Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. 
  • Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. 
  • Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. 
  • Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. 
  • Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96. 
  • Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. 
  • Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. 
  • Visualizing DNA replication in a catalytically active Bacillus DNA polymerase crystal. 
  • Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. 
  • What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction? 
  • When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. 
  • Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration? 
  • Will biosimilars gain momentum? 
  • Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. 
  • ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. 
  • [Evaluation of a rapid test using recombinant k39 antigen in the diagnosis of visceral leishmaniasis in Brazil ]. 
  • [Expression of recombinant human hemangiopoietin and preparation of its polyclonal antibody]. 
  • [Insulin producing cells as therapy in diabetes mellitus]. 
  • [Synthesis of human proinsulin in Escherichia coli cells]. 
  • alpha-Interferon and 5-fluorouracil: possible mechanisms of antitumor action. 
  • beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor. 
  • beta2-Adrenergic receptor regulation by GIT1, a G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein. 
  • ePAD, an oocyte and early embryo-abundant peptidylarginine deiminase-like protein that localizes to egg cytoplasmic sheets. 
  • hSnm1B is a novel telomere-associated protein. 
  • p45 NF-E2 regulates expression of thromboxane synthase in megakaryocytes. 
  • p53-dependent induction of heat shock protein 27 (HSP27) expression. 
  • pp60v-src kinase overexpression leads to cellular resistance to the antiproliferative effects of tumor necrosis factor. 
  • rHuEPO and improved treatment outcomes: potential modes of action. 
  • rHuKGF ameliorates symptoms in DSS and CD4(+)CD45RB(Hi) T cell transfer mouse models of inflammatory bowel disease. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Allori, Alexander C, Associate Professor of Surgery, Surgery, Plastic, Maxillofacial, and Oral Surgery
  • Bennett, Vann, George Barth Geller Distinguished Professor of Molecular Biology, Duke Cancer Institute
  • Bobay, Benjamin, Assistant Professor in Radiology, Radiology
  • Case, Laura Elizabeth, Associate Professor in Orthopaedic Surgery, Pediatrics, Medical Genetics
  • Chen, Jun, Professor of Medicine, Duke Cancer Institute
  • Cianciolo, George James, Associate Professor Emeritus of Pathology, Pathology
  • Cohen-Wolkowiez, Michael, Kiser-Arena Distinguished Professor, Pediatrics, Infectious Diseases
  • Erickson, Harold Paul, James B. Duke Distinguished Professor Emeritus, Cell Biology
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Ferreira, Paulo Alexandre, Associate Professor in Ophthalmology, Pathology
  • Freemark, Michael Scott, Robert C. Atkins, M.D. and Veronica Atkins Distinguished Professor of Pediatrics, in the School of Medicine, Pediatrics, Endocrinology
  • Hirschey, Matthew, Associate Professor of Medicine, Cell Biology
  • Hogan, Brigid L. M., Research Professor of Cell Biology, Cell Biology
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Integrative Immunobiology
  • Krangel, Michael S., George Barth Geller Distinguished Professor of Immunology, Integrative Immunobiology
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Luftig, Micah Alan, Professor of Molecular Genetics and Microbiology, Cell Biology
  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Shinohara, Mari L., Professor of Integrative Immunobiology, Cell Biology
  • Soderling, Scott Haydn, George Barth Geller Distinguished Professor of Molecular Biology, Cell Biology
  • Starmer, Charles Franklin, Professor Emeritus of Computer Science, Computer Science
  • Tsalik, Ephraim, Adjunct Associate Professor in the Department of Medicine, Medicine, Infectious Diseases
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology